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I. Clinical aspects of RCC 
Epidemiology and natural history 
Renal cell carcinoma is the most common tumor of the adult kidney. 
Approximately 80-90 % of all primary renal neoplasms are RCC (1). As a consensus, 
the origin of RCC cells are considered the proximal tubular epithelial cells, as 
evidenced by phenotyping and electromicroscopy (2,3).The incidence and frequency 
in the United States are approximately 8/100,000 per year and 2 % of all malignancies 
respectively, and the male to female ratio is approximately 2:1 (1,4). The average age 
at diagnoses is 55-60 years, and the peak age is between the sixth and seventh decade, 
but the disease can be found at any age (1,4). Postmortem studies with a large number 
of autopsies revealed that in many cases clinically non-manifest RCC existed (5-7). 
The clinical behaviour of RCC is sometimes very unpredictable. In general, the 
disease remains silent for many years and patients are often diagnosed with high stage 
disease. The most common symptoms are hematuria either macroscopically or 
microscopically, flank pain and palpable mass (so-called classical triad). However this 
clinical triad is observed only in 5-9 % of patients (8,9) and is a late stage feature. As 
a consequence of the improvement of diagnostic techniques, early stage, localized 
small tumors are found more frequently, influencing the incidence and survival rates 
(10,11). Approximately 23 % of patients will have metastases at presentation (12). 
Occasionally, spontaneous regression of metastatic sites after removal of the primary 
tumor is observed (less than 1 %), mostly in lungs, not in liver, brain or bone. The 
disease may reappear after being dormant for more than a decade, and the size of the 
metastatic tumor burden may vary in time (12). These phenomena seem to correlate 
to the hosts' immune status. Approximately 50 % of the RCC patients have clinically 
localized tumors and when RCC is confined to the kidney 65 % of patients is cured 
by radical surgery (13,14). However, the prognosis of the patients with progressive 
disease after radical nephrectomy for a localized tumor is poor (14). 
Substantial differences in the age-adjusted incidence of kidney tumors between 
countries have been observed, e.g., people in Scandinavian countries are at high risk, 
natives of Japan and other Asian countries are at low risk. Interestingly, the incidence 
of RCC of immigrant populations will slowly rise or fall to the incidence of the native 
population, suggesting the influence of an environmental factor. 
The etiology of RCC is not clear. Etiologic factors suggested are smoking, 
coke, cadmium, lead, and asbestos (4,15). Among these, cigarette smoking appeared 
to be a significant risk factor (15,16). Hereditarily, patients with von Hippel-Lindau 
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disease (VHL) have a high incidence of RCC (17). Recently, the putative VHL gene 
has been identified (18). However, the gene involved seemed dissimilar from RCC-
associated genes. RCC may develop in acquired cystic disease of the kidney in renal 
failure patients receiving long term hemodialysis (19,20). 
Cytogenetic analyses of familial and sporadic RCC revealed that genes on 
chromosome 3p are involved in the pathogenesis of RCC (21-28), e.g., Kovacs and 
Frisch demonstrated that 71 of 75 sporadic non-papillary RCC contained alterations 
on chromosome 3p (16). Abnormalities on other chromosomes have been found as 
well, e.g., monosomy 14, trisomy 7, and loss of Y chromosome (22,29,30), and 
recently an inverse correlation between allelic loss at chromosome 3p and 17p has 
been shown (31). A number of known oncogenes, growth factors, and growth factor 
receptors have been investigated in RCC, e.g., Η-ras, K-ras, c-myc, c-fos, c-erbB-1, 
and -2 (21,32-36). The proto-oncogene c-erbB-2 which has a high homology with the 
epidermal growth factor (EGF) receptor gene, has been described to be amplified in 
RCC (37). Enhanced expression of transforming growth factor a and ß (TGF-α, ß) 
was observed in RCC as compared to normal kidney (38) and recently it has been 
shown that serum basic fibroblast growth factor level was highly elevated in advanced 
RCC patients (33). 
Staging and pathological classification 
Several classification systems of RCC have been suggested to predict the 
clinical course of patients. At present the most commonly used staging systems are the 
UICC TNM classification (39)(Table 1) and Robson staging (40) (Table 2). The TNM 
classification appears to be more useful and reliable, because it defines the anatomic 
extent of the disease in detail, e.g., tumor size, involvement of renal vein/vena cava, 
regional lymph node invasion and distant metastases, factors that have been shown to 
be the main prognostic indicators for RCC (41-43). However, many clinicians still use 
the Robson classification, probably because the Robson staging is surgically practical. 
In RCC, three cell types are common (44,45): 
1) clear cells (30-40%); round and polygonal cells with optically empity cytoplasm 
containing glycogen and lipids. 
2) granular cells (10-15%); eosinophilic granular cytoplasm, rich in mitochondria and 
cellular organelles. 3) spindle cells (3-10%); spindle shaped and pleomorphic 
resembling cells, representative of the highest tumor grade. 
All cell types may be present in one tumor with different pathological patterns. 
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Table 1. 
TNM classification UICC (Third ed, 2nd revision 1992) 
Τ Primary tumor 
TO No evidence of primary rumor 
T l Tumor < 2 . 5 cm limited to the kidney 
T2 Tumor > 2 . 5 cm limited to the kidney 
T3a Invasion of adrenal gland or perinephric tissue but not beyond Gerota's fascia 
T3b Extension into renal vein(s) or vena cava below diaphragma 
ТЗс Extension into vena cava above diaphragma 
T4 Invasion beyond Gerota's fascia 
N Regional and juxt a regional lymph nodes 
NO No identifiable positive nodes in a specified clinical assessment 
N1 Single lymph node < 2 cm 
N2 Single lymph node > 2 cm but < 5 cm or multiple lymph nodes, none more than 
5 cm 
N3 Single or multiple lymph node > 5 cm 
M Distant metastases 
MO Tumor without distant metastases 
Ml Distant metastases including metastases in lymph nodes other than regional 
V Venous invasion (post surgery) 
VI Renal vein involvement 
V2 Vena cava below the hepatic veins 
V3 Vena cava above the hepatic veins 
Table 2. 
Robson's staging TNM (UICC 1992) 
Confined to the kidney 
Perinephric fat involvement 
Renal vein/vena cava involvement 
Regional lymph nodes involvement 
Vein and lymph nodes involvement 
Infiltrating adjacent organs 
Distant metastases 
Stage 
Stage 
Stage 
Stage 
I 
II 
Ilia 
Illb 
IIIc 
IVa 
IVb 
Tl-2 
T3a 
T3bc 
NO 
NO 
NO 
Tl-3a N1-3 
T3bc 
T4 
Tl-4 
N1-3 
N0-3 
N0-3 
MO 
MO 
MO 
MO 
MO 
MO 
Ml 
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Table 3. Prognostic parameters in RCC 
Τ 
N 
M 
V 
tumor 
size 
grade 
cell 
type 
Skinner 
et al. (8) 
n=309 
+ 
+ 
+ 
-
ND 
+ 
+ 
McNichols 
et al (48) 
η=506 
+ 
+ 
+ 
-
ND 
+ 
-
Seih 
et al. (41) 
n = 115 
+ 
ND 
+ 
-
ND 
+ 
+ 
Nurmi 
et al (55) 
n=257 
+ 
+ 
+ 
+ 
-
+ 
-
Bassil 
et al (42) 
η=252 
+ 
+ 
+ 
+ 
ND 
ND 
ND 
Golimbu 
et al (49) 
n=326 
+ 
+ 
+ 
-
+ 
ND 
+ 
Giuliani 
et al (56) 
n=200 
+ 
+ /-
+ 
+ 
+ 
+ 
-
+ ;significant, - ;not significant 
ND; not determined 
Prognosis 
Patients with RCC have a poor prognosis with an overall 5 year survival rates 
of approximately 40-60 % (8,40,41,47-50). Various factors have been investigated for 
their prognostic value, e.g., tumor size, stage, cell type, grade, involvement of vein 
and presence and number of metastases (8,40-43,46-56). Table 3 shows the prognostic 
significance of parameters studied by several investigators (8,41,42,48,49,55,56). 
Numerous studies have shown that stage and grade are the most reliable and 
consistent prognostic parameters (8,40-43,46-51). The prognostic significance of renal 
vein invasion is debated (8,41,48,52), however the most important factor which affects 
survival is the presence or the absence of metastases. The 5 year-survival rates of 
patients with metastatic RCC are 5-10 % and 10 year-survival rates are 0-7 % (47). 
Approximately, 23 % of patients have metastases at first diagnosis, and 25 % 
of patients who have a localised tumor in the kidney will develop metastases within 
5 years (12). Metastases can develop through hematogenic and lymphagenic pathways, 
and common metastatic sites are lung (55 %), lymph node (34 %), liver (33%), bone 
(32 %), adrenal gland (19 %), opposite kidney (11 %) and brain (6 %) (54). Whether 
a correlation between survival and cell types of RCC, i.e., clear cell, granular cell, 
and mixed cell type exists is unclear (53). However, patients with RCC mainly 
composed of spindle cells have the poorest prognosis (51,52). Patients with pure 
papillary RCC have a relatively favourable prognosis (46). 
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In addition to the above mentioned prognostic factors, recently, nuclear 
morphometry and DNA content have been investigated in RCC (57-60). Several 
investigators have shown a correlation between ploidy and survival (57-59). However, 
other investigators were unable to confirm these results (60, 61). In the flowcytometric 
studies, considerable heterogeneity of tumor cell populations was observed in RCC, 
which might explain this seeming discrepancy. 
Therapeutic strategies 
1) Surgery 
Presently, extensive radical surgery is the only effective therapy for RCC, 
provided that all tumor tissue can be removed. The indication of nephrectomy in 
metastatic RCC is still controversial. Limited cases may benefit from this procedure, 
e.g., for patients with good performance status and a solitary metastatic lesion, or for 
palliative purposes (62). 
2) Radiotherapy 
RCC is not radiosensitive. Radiotherapy dose not result in a prolongation of 
survival and is indicated only for palliative treatment, e.g., for painful bone metastases 
and symptomatic metastases of the nervous system (63,64). 
3) Hormonal therapy 
Initial studies with medroxyprogesterone showed an objective response rate of 
16% with little toxicity (65). However, subsequent trials with androgens, 
progestérones and antiestrogens resulted in response rates of less than 5% (66). 
4) Chemotherapy 
Despite the fact that chemotherapy of metastatic RCC has been studied 
extensively, the objective response rates have been disappointing. Clinical trials with 
most single agents resulted in response rates of less than 10% (1). Vinblastine is the 
most effective agent with response rates up to 15% (67). Vinblastine based 
combination chemotherapy have failed to provide better results over single agent 
treatment. 
The reason that most cytotoxic agents are ineffective (so-called multidrug 
resistance;MDR) is not clear but may be due to the activity of P-glycoprotein which 
serves as an efflux pump. It has been shown that elevated levels of the mdr-I gene (P-
glycoprotein encoding gene) and the gene product is associated with resistance to 
cytotoxic drugs (68-70). Because proximal tubular cells, generally considered to be the 
progenitor cells of RCC (2,3), express P-glycoprotein, it is not surprising that RCC 
cells are insensitive to chemotherapy (69-70). 
5) Immunotherapy 
RCC displays a unique biological behaviour. Most striking are the occasional 
15 
spontaneous regression of metastatic disease and the occasional long dormancy of 
metastases. Investigations considering the immune status of RCC patients seem to 
indicate that the biological behaviour of the tumor is influenced by the immune system 
(12). Therefore, immunotherapy, both active and passive, specific and non-specific, 
seemed to be an attractive therapeutic alternative for RCC. The first choice of active 
specific immunotherapy is a tumor vaccine. Tykkä et al. treated advanced RCC 
patients with polymerized autologous tumor cells after palliative nephrectomy and 
reported a significant improvement of survival as compared to non-treated patients 
(71,72). However, subsequent investigators failed to demonstrate any effect of 
autologous tumor vaccination in RCC patients (73-75). Initial attempts of non-specific 
immunotherapy involving immunomodulation of patients with Bacillus Calmette-Guerin 
(BCG) resulted in a 5% response rate (76). 
The development of biological response modifiers (BRMs) permitted their use 
as new immunotherapeutic agents for the treatment of metastatic RCC. Numerous 
clinical studies with different doses of cytokines and different schedules have resulted 
in response rates (complete + partial remission; CR + PR) between 8 and 35% (table 
4). Non-specific immune modulation with interferon-alpha (IFN-a), interferon-beta 
(IFN-ß) or their combinations resulted in response rates between 3 and 27 % (77-87). 
Fossa et al. investigated the efficacy of IFN-a with or without vinblastine (88). This 
treatment resulted in response rates between 8 and 42 % (80,88-90). Interleukin-2 (IL-
2) treatment resulted in response rates between 12 and 21 % (91-93) and combination 
of IL-2 with IFN-a resulted in 30-31 % response rates (91,94,95). Although IL-2 
based combination therapies were performed with different doses and schedules, 
similar response rates were observed. Tumor Necrosis Factor alpha (TNF-a) has been 
used in phase I clinical trials resulting in minor responses with considerable toxicity 
(96). Up to now, the benefit of TNF treatment of RCC patients is unclear. 
Rosenberg et al. developed adoptive cellular therapy, i.e., reinfusion of in vitro 
IL-2 primed and cultured autologous immune cells into the patients (91). IL-2 
treatment with autologous lymphokine activated killer (LAK) cells or with tumor 
infiltrating lymphocytes (TIL) have shown 9-35 % response rates (91,92,97,98), 
slightly higher than chemotherapeutics. However, no significant improvement of 
prognosis was observed (91,99). Recently, RCC specific cytotoxic Τ lymphocytes 
(CTL) have been isolated from TIL of RCC (100). The approach of Τ cell targeted 
cancer therapy holds considerable promise provided that the CTL is RCC-specific. 
The use of monoclonal antibodies (MAb) specific for a tumor-associated antigen 
(TAA) as passive specific immunotherapy is also feasible. Cancer immunotherapy with 
MAbs have been reported in other cancers, e.g., melanoma, colon, lymphoma (101). 
Some complete responses were observed but response rates were low and the duration 
of the anti-tumor responses were short (102). Several antibodies have been generated 
against RCC-associated antigens. Most of these antibodies, however, react with 
antigens expressed on various normal tissues, most notably, proximal tubules of the 
kidney (103). A number of MAbs recognize antigens expressed on RCC and absent 
from normal kidney tissue (104-108). 
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In a number of clinical studies, the use of MAbs for diagnostic applications, 
i.e., radioimmunoscintigraphy has been investigated (109). Very few data from 
therapeutic clinical trials are available (109,110). In a phase I study with murine MAb 
F23, 14 advanced RCC patients were treated with escalating protein doses and only 
one patient showed a partial response (111). In all patients, human anti-mouse 
antibody (HAMA) responses were observed hampering additional MAb treatment. 
Although immunotherapy seems to be the most promising treatment modality 
of RCC, surgery still remains the only way to cure RCC patient; Clearly, new 
strategies are necessary to develop new effective anti-RCC agents. 
Most human malignancies and spontaneous animal tumors have weak, if any, 
detectable immunogenic properties and unequivocal evidence for the existence of 
unique tumor-specific antigens in human malignancies is still lacking, despite a 
worldwide extensive search. These observations have led to the conclusion that human 
cancers are either non-immunogenic, i.e. do not express tumor-specific antigens, or 
mediate strong immunoregulatory effects. In that regard, RCC may be an exception. 
The observation of occasional -0.5 to 1.0%- spontaneous regression of metastases in 
(RCC) patients is suggestive for a host defense mechanism against the tumor 
(112,113). Ritchie et al. have shown that RCC patients have a deficit in Th cells as 
well as a decrease of (poorly defined) antibodies against their tumors with disease 
progression (114). Th cell numbers increased significantly in RCC patients following 
nephrectomy, whereas with progression of disease the deficit reappeared (114). In 
addition, Ueda et al. were able to detect a unique RCC antigen in one of 28 RCC sera 
examined with autologous typing (115). These results indicate that RCC patients can 
raise an (abortive) immune response against as yet unknown target structures present 
on their tumor. Numerous clinicians and immunologists have been looking for new 
strategies to manipulate the host's immune system specifically to combat human 
malignancies. 
Table 4. BRM based clinical trials 
Therapy 
IFN-β 
Krown (77) 
Umeda & Nüjima (78) 
Muss et al. (79) 
Neidhart et al. (80) 
IFN-y 
Takakuetal . (81) 
Garmick et al. (82) 
Bruntsch et al. (83) 
IFN-a + y 
Foon et al. (84) 
Quesada et al. (85) 
Debruyne et al. (86) 
Ernstoft et al. (87) 
IFN-a+Vinblastine 
Bergerat et al. (89) 
Schornagel et al. (90) 
Neidhart et al. (80) 
IL-2 
Rosenberg et al. (91) 
Stoter et al. (92) 
Bukowski et al. (93) 
IL-2+IFN-« 
Rosenberg et al. (91) 
Atzpodien et al. (94) 
Négrier et al. (95) 
IL-2+LAK 
Rosenberg étal. (91) 
Négrier et al. (97) 
Stoter et al. (92) 
Parkinson et al. (98) 
No.of 
Pts 
62 
108 
97 
82 
62 
41 
32 
47 
46 
50 
30 
40 
56 
83 
52 
35 
41 
35 
43 
35 
72 
32 
44 
47 
Response rates 
CR PR 
0 
2 
2 
2 
1 
1 
0 
0 
0 
6 
2 
1 
0 
3 
4 
2 
1 
4 
4 
1 
8 
2 
4 
2 
7 
13 
6 
8 
7 
3 
1 
2 
5 
7 
6 
16 
9 
4 
7 
4 
4 
7 
6 
6 
17 
4 
8 
2 
%0f 
CR+PR 
11 
14 
8 
12 
13 
10 
3 
4 
19 
26 
27 
42 
16 
8 
21 
17 
12 
31 
30 
30 
35 
19 
27 
9 
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II. Anti-idiotype antibodies 
To clarify the immunological terminology, a glossary of terms used in this 
thesis is given 
Epitope: antigenic determinants on macromolecules represented by 
proteins, carbohydrates, etc. 
Idiotope: a single antigenic determinant on the variable (V) region of an 
immunoglobulin molecule. 
Idiotype: collection of idiotopes on an individual antibody molecule. 
Paratope: antibody-combining site 
Abl antibodies that are induced by the initial antigen 
Ab2 antibodies directed against idiotopes of Abl (so-called anti-
idiotype antibodies) 
Ab3 antibodies directed against idiotopes of Ab2 (so-called anti-anti-
idiotype antibodies) 
internal image: the idiotype is made up of a collection of individual idiotopes. If 
the idotope and paratope are identical, antigen-Abl and Abl-Ab2 
interactions may involve a concave-convex model, i.e., Ab2 and 
the antigen share structurally similar antigenic determinants. In 
this case, Ab2 functionally mimics the nominal antigen, i.e., 
represents the internal image of the antigen: Alternatively three-
dimensional structural mimicry of the original antigen is not 
absolutely necessary (116). 
Idiotype regulation (Idiotype Network Theory) 
The idiotype network concept is based on the hypothesis that a variable region 
of an immunoglobulin molecule itself comprises a new antigenic determinant. 
Therefore, it will induce anti-antibodies which again bear new antigenic determinants. 
Fig. 1. shows a schematic representation of the V region of an immunoglobulin, and 
the relationship between idiotopes and an epitope (117). 
The concept that immune responses might be regulated by idiotype -anti-
idiotype interactions was proposed by Niels Jerne in 1974 (117). He hypothesized that 
idiotype-anti-idiotype interactions may regulate the hosts' immune responses through 
positive (enhancing) as well as negative (suppressing) feed back mechanisms. In this 
concept, the idiotopes of an antibody play a major role in the immune response. The 
antibodies elicited by the V region of Abl, anti-idiotype antibodies (Ab2), can be 
divided into 3 types; i) Ab2 binding near the combining site (paratope) of Abl and 
interfering with antigen binding (Ab2a), ii) Ab2 mimicking the structure of the antigen 
recognized by the initial antibody (Abl)(so-called "internal image" antibodies; Ab2ß), 
iii) Ab2 binding to idiotopes remote from the paratope of Abl (Ab2c)(118). 
combining site (paratope) 
Immunoglobulin 
epitope on normal 
antigen 
idiotope 
Fig. 1. Antigenic constitution of variable domain. The antigenic determinants on the antibody V 
region are referred to as idiotopes. Some idiotopes are located inside the combining site (paratope) 
and some are outside the paratope. The collection of all idiotopes on V region is termed the idiotype 
of the antibody. Determinants on the antigen presenting molecule are termed epitopes. 
Fig. 2. shows a schematic framework of the idiotype network. The antigen 
elicits antibodies (Abl) which bear the original idiotype. Abl bears a number of 
idiotopes. Anti-idiotope antibodies are generated by Abl and stimulate idiotype 
regulation. Then anti-idiotype antibodies stimulate anti-anti-idiotype antibodies. Thus, 
within the network, Abl are regulated by Ab2, Ab2 are regulated by Ab3, etc. Ab2 
directed against idiotopes within the combining site (Ab2ß) can be distinguished from 
Ab2 directed against idiotopes outside the combining site. 
Considering that Ab2ß has an idiotope resembling the initial antigen, i.e., bears 
the internal image of the antigen, this type of Ab2 can induce Ab3 reacting with the 
original antigen, since Ab3 and Abl share similar idiotopes, i.e., functionally mimic 
each other (see Fig. 2). This type of Ab3 is referred to as Abl' (Abl-prime). Other 
antibodies (АЬ2а,б) are able to recognize idiotopes on the original idiotype but do not 
mimic the paratope. 
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Experimental evidence has supported the presence of internal image Ab2 
(119,120). Numerous investigators have shown that antibodies mimicking the structure 
of the initial immunogen can be found (119,121-129). It has been suggested that Ab2 
might be used as a surrogate antigen for vaccination to trigger the hosts' immune 
system against the nominal antigen (130,131). Additionally, spontaneously produced 
anti-idiotype antibodies have been detected in several autoimmune diseases, e.g., 
rheumatoid arthritis (132), systemic lupus erythematosus (133-135), myasthenia gravis 
(136,137), autoimmune thyroiditis (138,139), etc. Emphasizing that in these patients 
with auto-anti-idiotype antibodies, the inverted correlation of high levels of Ab2 with 
low levels of Abl was observed, suggesting suppressive effects of Ab2 (idiotype 
negative feedback)( 131). 
In the initial network hypothesis, no attention was given to the Τ cell arm of 
the immune system (117). There is evidence that anti-idiotype antibodies can modulate 
the hosts' immune responses through Τ cell cascades (140-142). It has been 
hypothesized that one of the two distinguishable Τ helper (Th) cell subsets, i.e., Thh2 
is important in idiotype network regulation (141, 143). The induction of specific Th 
cell responses by anti-idiotype vaccination has been observed: e.g., vaccination with 
anti-idiotype antibodies induced idiotype-specific Th cells distinguishable from antigen-
specific Th cells (143). Induction of Τ cell responses has been also shown for tumor-
specific delayed-type hypersensitivity induced by Ab2 vaccination (144-146). 
Therapeutic applications of anti-idiotype antibodies 
The first therapeutic application of Ab2 was their use as vaccines for infectious 
deseases, e.g., as substitute for parasites, viruses and bacteria. Vaccination of animals 
with Ab2 resulted in the induction of anti-parasitic, anti-viral or anti-bacterial reactions 
(141,130). However, the protective potential elicited by Ab2 vaccinations was less as 
compared to the original vaccines. Nevertheless, Ab2 vaccinations were sufficient to 
prevent infections. For example, vaccination of chimpanzees with internal image Ab2 
mimicking the surface antigen of hepatitis В virus resulted in the protection from 
hepatitis В virus infection whereas control animals developed clinical and serological 
signs of infection (147). In some diseases, vaccines may be difficult or impossible to 
make, therefore idiotype vaccination may provide a suitable alternative. 
The investigations of idiotype vaccines have led clinicians and immunologists 
to try to implement Ab2 for cancer therapy. Since Ab2 should be able to substitute for 
the nominal antigen, idiotype vaccines consisting of MAbs bearing the internal image 
of a tumor-associated antigen (TAA) may provide attractive new therapeutic 
modalities. Recently, a number of investigators have developed Ab2 against anti-TAA 
antibodies, which functionally mimic the original ТА As in animal systems (148-160). 
Most striking, in an animal system, Ab2 vaccination resulted in the induction of 
antibodies bearing the internal image of the initial TAA (АЬГ), whereas immunization 
with TAA presenting cells did not induce АЬГ (161), showing that the different 
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presentation of the TA A resulted in enhanced immunogenicity. 
Recently, several investigators have reported clinical studies with Ab2s in 
melanoma and colorectal cancer (162-165). Mittelman et al. immunized melanoma 
patients with a mouse Ab2 MK2-23 bearing the internal image of the high-molecular-
weight melanoma-associated antigen (HMW-MAA), and found anti-HMW-MAA 
antibodies in 60 % of immunized patients and prolongation of their survival (166). 
Adler et al. carried out 2 phase I trials to evaluate the effects of Ab2 
MELIMMUNE™-2 alone or Ab2 mixed with adjuvant, and demonstrated that Ab2 
plus adjuvant resulted in a significant higher Ab Γ titer, however, mild toxicity was 
observed (163). In colorectal cancer, Durrant et al. treated advanced stage patients 
with a human Ab2 105AD7 on alum (165) and demonstrated a significant 
improvement in survival: median survival 12 months in immunized patients compared 
to 4 months in unimmunized patients. The results obtained in these trials indicate that 
indeed internal image Ab2 may represent new therapeutic agents. 
Induction of cellular mediated immunity against syngeneic and non-syngeneic 
tumors by Ab2s has been investigated in a number of tumor types 
(143,145,146,159,167,168). Several investigators demonstrated that tumor specific 
cellular immune response induced by Ab2s vaccination play an important role 
(143,167). For example, Dunn et al. demonstrated protection against tumor challenge 
by syngeneic Ab2 vaccination without a concomitant humoral response, indicating that 
successful Ab2 vaccination did not require the production of high titers of АЬГ in 
serum (167). Ab2 vaccination can result in tumor-specific delayed-type-
hypersensitivity in animal systems (145,152). 
ΠΙ. Aim and outline of this thesis 
Aim 
Since Köhler and Milstein described the production of monoclonal antibodies 
(MAbs) (169), a number of M Abs recognizing RCC-restricted and RCC-associated 
antigens have been described (104-108). Some of the MAbs detect antigens expressed 
by the tumors only (105,106), some MAbs recognize kidney-differentiation antigens 
(104-106), and some recognize antigens aberrantly expressed by the tumor cells, i.e., 
expressed in a restricted number of tissues, but not expressed in normal adult or fetal 
kidney tissue (104,107,108). The number of unique RCC antigens identified through 
MAbs is remarkably high in comparison to other tumor types. The fact that RCC is 
among the most responsive tumors to adoptive cellular therapy may be related to the 
expression of such unique RCC antigens. Expression of these antigens might be 
induced by local cytokine production by tumor infiltrating cells (170). These unique 
or aberrantly expressed structures might function as targets in an immune response. 
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Fig. 3. Production of internal image antibodies directed against MAbG250. The idiotope of Ab2 
mimics RCC-TAA, i.e.» the "internal image" of TAA. Immunization with Ab2 elicits АЬЗ mimicking 
Abl (so-called Ab Г). 
MAbG250 was described to be specifically reactive with RCC (108,171). The 
G250 antigen is homogeneously expressed in 90% of RCC examined and is absent 
from kidney and other normal tissues with the exception of gastric mucosal cells and 
cells of the larger bile ducts (108,171). Based on its restricted expression in normal 
tissues and homogeneous expression in most RCC, it was of considerable interest to 
produce internal image anti-idiotype antibodies directed against the combining site of 
MAbG250. These might be used as RCC tumor vaccines and might elicit anti-TAA 
immunity, e.g., АЬЗ recognizing the initial TAA (Fig. 3). 
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Outline 
Effective treatment for patients with disseminated RCC is currently lacking. 
Despite intensive efforts, the five year survival of these patients is extremely poor. In 
this thesis, we evaluated the potential of MAbG250 recognizing a RCC-associated 
antigen, and monoclonal anti-idiotype antibodies raised against MAbG250. 
To evaluate the therapeutic potential of MAbG250, we investigated the anti­
tumor effects of cytokines (IFN-a, r, TNF-a) and/or MAbG250 in mice with 
established RCC xenografts. The results of treatment with cytokines and/or MAbG250 
are presented in Chapter II. In the third chapter, the isolation and characterization of 
six different anti-idiotype antibodies (NUH31, 51, 71, 82, 91;IgGl, NUH44;IgG2a) 
are presented (Chapter III). 
To evaluate whether these six Ab2 could induce antigen-specific cell mediated 
immunity, delayed-type hypersensitivity (DTH) tests with Ab2 sensitized mice were 
carried out. To confirm the cellular nature of the DTH responses, lymphocytes or 
serum harvested from mice sensitized with Ab2 were transferred to naive mice which 
were subsequently challenged with antigen-positive and -negative cells. The results of 
this study are presented in Chapter IV. 
To further investigate the potential usefulness of these Ab2, we characterized 
their ability to induce tumor antigen specific humoral responses in mice and rabbits, 
investigated whether the immunogenicity of the Ab2 could be enhanced by conjugation 
to carriers, and carried out fine specificity studies of Ab3 sera (Chapter V). 
The latter study indicated that the six Ab2 could be divided into four distinct 
groups. To investigate whether any of the Ab2 showed superior anti-tumor efficacy 
as compared to the other Ab2, a possible reflection of subtle differences, in vivo 
tumor protection experiments with human RCC cells were carried out by Ab3 scrum 
transfer (Chapter V). The therapeutic efficacy of Ab3 sera was also investigated in 
mice with established human RCC xenografts. In addition, the treated tumors were 
analyzed histopathologically (Chapter VI). 
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ABSTRACT 
Because renal cell carcinoma (RCC) is considered relatively resistant to radio-
and chemotherapy, RCC patients may benefit from new treatment modalities, e.g. 
immunotherapy. In vitro and in vivo studies suggest that combinations of cytokines 
such as interferon gamma or interferon alpha (IFN-7, IFN-a) and tumor necrosis 
factor alpha (TNF-a) may act synergistic. In this study we tested whether a 
monoclonal antibody (mAb) G250, reactive with a RCC-associated antigen, showed 
antitumor effects in vivo in nude mice with established subcutaneous human RCC 
xenografts, and also whether this mAb G250 could enhance the antitumor effect of 
combinations of IFNs and TNF-a. Treatment with mAb G250 alone or combinations 
of IFN-a/TNF-a, or IFN-r/TNF-α, resulted in a significant tumor growth inhibition. 
Treatment with mAb G250 in combination with IFN-7/TNF-a did not result in 
improved antitumor effect as compared to both treatments alone. In contrast, mAb 
G250 combined with IFN-a/TNF-a resulted in a significantly enhanced antitumor 
response. In one experiment, 3 out of 10 mice showed complete tumor regression, 
with no recurrence after 90 days. Large numbers of infiltrating macrophages were 
found surrounding viable and necrotic tumor tissue after treatment with G250 
combined with IFN-a/TNF-a. These results suggest that combination therapy, 
consisting of IFN-a, TNF-a and mAbs, may have therapeutical value in the treatment 
of RCC. 
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INTRODUCTION 
Immunotherapy using high doses of recombinant human cytokines such as 
interferon (IFN) and tumor necrosis factor (TNF) has resulted in antitumor effects 
both in animal models and in patient studies (Baisch et al., 1990; Beniers et al., 
199lu). Although complete tumor regressions after therapy with IFN-α or IFN-r have 
been observed, the overall response rate in RCC patients is only of the order of 10-
30% (Foon, 1989). Also for TNF-a clinical trials have been initiated (Creagan et ai, 
1988). However, severe toxicity associated with high dose cytokine regimens is a 
major obstacle for treatment of patients with metastatic cancer (Creagan et al.t 1988). 
The mechanisms of the antitumor effects initiated by these cytokines are not fully 
understood. However, in vitro and in vivo studies have shown that IFN-a enhances 
MHC Class I and II antigen expression on the cell surface of normal and malignant 
cells (Weber and Rosenberg, 1988; Beniers et ai, 1991¿), up-regulates tumor-
associated antigens (Greiner et al, 1987; Murray et ai, 1990) and has direct cytotoxic 
effects on tumor cells (Baisch et ai, 1990). IFN-τ, like IFN-α, has in addition to its 
direct antiproliferative effects on tumor cells (Ramani etaL, 1986) also indirect effects 
by modulation of the immune system, such as induction of NK cell activity (Dempsey 
et ai, 1982). Furthermore, activation of monocytes and induction of monocyte Fc-
receptor expression (Lübeck et al., 1985) has been described. 
TNF-a can also be directly antiproliferative (Baisch et al., 1990). Binding of 
TNF-a to specific TNF-receptors on the cell surface can trigger cell kill due to the 
release of intracellular lysosomal enzymes and the production of free radicals 
(Haranaka, 1988). Furthermore indirect antitumor effects of TNF-a, due to the 
destruction of the vascular endothelium in the tumor bed have been described 
(Palladino et al, 1987). Similar to the two previously discussed cytokines, TNF-a has 
immunomodulatory functions such as enhancement of macrophage and NK activity 
(Keller etaL, 1990), and induction of expression of Fc-receptors on macrophages and 
NK cells (Hoffman and Weinberg, 1987). TNF-a, in contrast to IFN-τ, can induce 
Fc-receptor expression on mouse immune cells. 
In vitro studies have shown that combinations of IFN-a, IFN-τ and TNF-a can 
act synergistic or additive with respect to antitumor activity (Nissen-Meyer et al., 
1988; Beniers et al., 1989). In in vivo studies in nude mice xenografted with human 
tumors, a synergistic effect of combinations of TNF-a and IFN-α or IFN-r was 
observed (Baisch et al, 1990; Beniers et al., 1991α). Treatment of relatively large 
tumors, however, never resulted in complete tumor eradication, but did show 
retardation of tumor growth. 
As already mentioned before, toxic effects associated with the high doses of 
IFN-α and TNF-a needed for therapeutic effects are a major drawback for human 
therapy. In this respect, in vivo experimental data show that the antitumor effect of 
cytokines can be enhanced by monoclonal antibodies (mAbs) reactive with tumor 
associated antigens present on melanoma (Gridley etaL, 1989; Eisenthal etaL, 1990), 
and murine lymphomas (Vuist et al., 1990). This may allow for a significant decrease 
of the cytokine doses without compromising the efficacy. In studies with mAbs 
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reactive with appropriate target antigens, the increased presence of Fc-receptors on 
monocytes and NK cells after IFN-r treatment resulted in enhanced ADCC of target 
cells in vitro and in vivo (Weiner et αι., 1988). 
In the present study we investigated whether the anti-RCC mAb G250, reactive 
with 95% of primary and with 86% of metastatic RCC (Oosterwijk et al., 1986), 
shows in vivo antitumor effects on established RCC xenografts of significant size. 
Because of the preferential expression of G250 antigen in RCC (Oosterwijk et ai, 
1986) and because of its cytotoxic potential for RCC tumor cell lines when used as a 
bispecific mAb in combination with activated peripheral blood lymphocytes (Van Dijk 
et al., 1989), mAb G250 alone or in combination with cytokines may have clinical 
potential in treatment of patients with metastatic RCC. 
Our earlier studies have shown that combination therapy of RCC with optimal 
doses of IFN-a/TNF-Q! or IFN-r/TNF-α, injected subcutaneously (s.c) around the 
circumference of the tumor, but not intravenously or intraperitoneally, resulted in 
complete eradication of tumor growth in 4 out of 8 different RCC grafted s.c. in nude 
mice, provided that at the start of treatment the tumor volume was less than 2 mm3 
(Berners et al., 1991α). Treatment of larger tumors never resulted in complete tumor 
eradication but did show retardation of tumor growth. To investigate any additional 
antitumor effects of mAb G250 we used this antibody together with the optimal doses 
of the combinations IFN-a/TNF-a and IFN-r/TNF-α, as established in the s.c. 
peri tumoral studies (Beniers et al., 1991α). 
MATERIAL AND METHODS 
Mice 
Six weeks old Balb/c nu/nu mice (Bomholtgàrd, Ry, Denmark) were used. The 
animals were adjusted to the experimental environment for two weeks before entering 
into experiments. Groups of 10 mice were kept in PAG type 3 cages covered with an 
iso cap (Iffa Credo, France) for sterile conditions. Sterilized sawdust (Iffa Credo 
Broekman b.v., The Netherlands) was used as bedding material. The mice were fed 
ad libitum with gamma irradiated (0.9 MR) SRM-A MM food (Hope Farms, 
Woerden, The Netherlands). Drinking water was acidified with 0.7 ml concentrated 
HCL/liter. Day/night rhythm was 12 hours light, 12 hours dark and the temperature 
was 22°C. Humidity in the experimental environment was unregulated. 
Renal cell xenograft 
The NU-12 RCC was established from a primary tumor by serial subcutaneous 
(s.c) transplantation (Beniers et ai, 1992). Tumor stage of the primary tumor was T3. 
For the in vivo treatment protocols we used the third to tenth transplant generation. 
Before transplantation, necrotic areas were carefully removed and tumor pieces of 1-2 
mm3 were implanted s.c. in the right flank of the mice. Xenografts were serially 
transplanted every 6 weeks. 
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Interferons and tumor necrosis factor 
Recombinant human IFN-a, IFN-r, and TNF-a were kindly provided by 
Boehringer Ingelheim. Specific activities of rIFN-a and rIFN-τ were 3.2.10* U/mg 
and 2Л07 U/mg protein, respectively. Both rIFN-α and rIFN-τ were >98% pure as 
determined by SDS Polyacrylamide gel electrophoresis and the amount of endotoxin 
was less than 1.0 ng/mg protein for rIFN-α and less or equal to 0.5 ng/mg protein for 
rIFN-7 as based on the limulus amoebocyte lysate assay. rTNF-a had a specific 
activity of 6.107 U/mg protein as determined in the presence of actinomycin-D (the 
L-929 cytotoxicity assay). The purity was >99% and contained 1.0 ng or less 
endotoxin/mg protein based on the limulus amoebocyte lysate assay. 
All drugs used were dissolved in the accessory solvent and further diluted with 
unsupplemented RPMI medium (GIBCO, Paisley, UK). After dilution, the drugs were 
stored in 1.2 ml aliquots at -80°C until use. 
Monoclonal antibodies 
The murine anti-RCC mAb G250 (isotype IgG2a) was developed in our 
laboratory as a class switch variant of the original clone. In immunohistochemistry, 
mAb G250 reacts with 95% of primary RCC and with 86% of metastatic RCC 
(Oosterwijkera/., 1986). 
The anti-myosin mAb C4 of IgG2a isotype, provided by Centocor, not reacting 
with RCC in immunohistochemistry, was used as a control mAb in this study. 
mAbs were purified from ascitic fluid on Protein-Α Sepharose (Pharmacia, 
Uppsala, Sweden). Ascitic fluid was centrifuged for 30 min. at 10,000 g, diluted 1:1 
with binding buffer (1.5M glycin, 3M NaCl, pH 8.9) and passed through a Protein-A 
Sepharose column. Bound immunoglobulin was eluted with 0.1 M citrate buffer pH 
4.0. The eluted fractions were pooled and dialyzed against PBS and sterilized through 
a 0.2 μ filter. mAbs G250 and C4 were stored in single dose aliquots at 4°C. 
Preparation of F(ab')2 fragments 
Protein-Α Sepharose purified G250 IgG mAb and pepsin (Cooper, Palo Alto, 
CA) were dissolved in 0.1M citrate, pH 4.3, at a concentration of 1.4 mg/ml and 1.0 
mg/ml, respectively. Digestion was performed for 20 hr at 37°C with a 1:100 (wt/wt) 
ratio of pepsin/Ig. The reaction was stopped by adding IM Tris-HCL buffer, pH 9.5, 
to reach a final pH of 7.0. The digestion product containing F(ab')2 fragments was 
purified from intact IgG on a Protein-Α column which was equilibrated with 1.5M 
glycin, 3M NaCl, pH 8.9, and diluted with 0.1 M citrate pH 3.0. F(ab')2 fragments 
were present in the flow-through, whereas undigested immunoglobulin was found in 
the acid eluate. F(ab')2 fragments were further purified by gel filtration on Superóse. 
Experimental design 
RCC tumors (NU-12), grown for 6 weeks in nude mice, were minced and one 
tumor piece of 1-2 mm3 was implanted s.c. in the right flank. Treatment groups were 
randomized and therapy was started when tumors measured approximately 50 mm3 
(10-14 days after implantation). Each experimental group contained 6-10 mice. The 
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animals were treated subcutaneously peritumoral 3 times a week during 6 weeks with 
rIFN-α or rIFN-7, and five times a week with rTNF-α. On the days the animals 
received both rIFN-α and TNF-a, or rIFN-r and rTNF-α, this combination was given 
as a cocktail (total injection volume was 200 μ\). Cytokines were administered s.c. 
around the circumference of the tumor. mAbs were given intraperitoneally 3 times a 
week. The doses used per injection were respectively: 
150 U/g body weight rIFN-a, 
30.000 U/g body weight rTNF-a:, 
150 U/g body weight rIFN-τ, 
500 μg mAb G250, 
500 /ig mAb C4 
Control mice were either left untreated, were treated peritumoral, s.c. with 
unsupplemented RPMI medium five times a week, in the same manner as described 
for the cytokines, or were treated with irrelevant mAb C4. Tumors were measured 
twice a week with a sliding caliper. Tumor volume was expressed as Tumor Size 
Index (T.S.I) and was calculated by the following equation: 
T.S.I (mm3) =L χ W χ Η /2 
where L, W, and Η represent maximum diameter, diameter at right angles to the 
length, and thickness, respectively. 
Immunohistochemistry of NU-12 xenografts 
Tissue samples of tumors were taken 2 days after the last treatment, snap-frozen 
and stored at -70°C. Representative tumors were examined for necrotic regions and 
tested in immunohistochemistry for the presence of G250 antigen and for the presence 
of infiltrating mouse macrophages. Immunohistochemistry was performed as described 
before (Van Muijen et al., 1984). Briefly, frozen tumor sections (4-6 μΐη thick), were 
airdried overnight and fixed in aceton for 10 minutes at room temperature. After 
washing with 0.05 M phosphate buffered saline, (pH 7.4; PBS) tissue sections were 
incubated for 60 minutes at room temperature with either mAb G250 (mouse IgG2a) 
or with mAb MAC-1 (rat IgG2b isotype; Serotec), known to react with both human and 
mouse macrophages. After washing with PBS, tumor sections were incubated with 
either rabbit anti-mouse immunoglobulin conjugated to horseradish peroxidase (HPO) 
for the detection of G250 antigen, or with rabbit anti-rat immunoglobulin conjugated 
to HPO, preincubated with normal mouse serum, for the detection of mouse 
macrophages. Tumor sections were developed by incubating tissue sections for 5 
minutes in sodium acetate buffer (0.05 M, pH 5.0), followed by incubation with 3-
amino-9-ethylcarbazole (AEC)/H202 for 7 minutes, the reaction was stopped by rinsing 
the slides in demineralized water. Tissue sections were counterstained with 
haematoxylin, dehydrated and mounted with Kaisers glycerol gelatin. 
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Statistical analysis 
The data were analyzed for statistical significance between groups using the 
Student-Newman-Keuls test. Ρ values less than 0.05 were considered as significant. 
RESULTS 
Antitumor effects of mAb G250 alone and in combination with rIFN-a/rTNF-a 
or rlFN-r/rTNF-a on s.c. growing established RCC NU-12 xenografts. 
Table 1 summarizes the results of two representative experiments of the effects 
of mAb G250 alone and in combination with rIFN-a/TNF-a or rlFN-r/TNF-a on the 
in vivo growth of established RCC NU-12 xenografts with an initial size of 30 to 50 
mm
1
. The tumor volumes for each of these experiments for each treatment schedule 
after 6 weeks of treatment are presented. 
Administration of 500 μg mAb G250 for 6 weeks with 3 weekly injections 
resulted in a significant inhibition of tumor growth (compared to untreated tumors 
(p <0.01). The difference between both groups became more pronounced after 45 days 
(Fig. 1A), because the tumor growth rate of untreated tumors accelerates around this 
time due to cyst formation (Beniers et al., 1992). Treatment with 500 μζ G250 F(ab')2 
fragments resulted in a slight tumor growth inhibition, although to a lesser extent as 
compared to mAb G250 (Table 1). Treatment with medium or irrelevant mouse IgG2a 
did not show any antitumor effects (Table 1). 
Treatment of tumors with doses of rIFN-a/rTNF-α, that had been shown to be 
optimal for small tumors (Beniers et al., 1991α), resulted in a significant inhibition 
of tumor growth (p<0.01). The mean tumor size was approximately 35-45% as 
compared to untreated tumors. Because tumor growth accelerates around 45 days after 
implantation (see above), the tumor growth inhibition by cytokines treatment was more 
prominent after 45 days of implantation (Fig. IB). No statistically significant 
differences were found between groups of mice treated with cytokines or mAb G250, 
i.e. both treatments seemed to be equally effective in tumor control. 
Combination of mAb G250 with rIFN-r/rTNF-α did not result in an enhanced 
reduction of tumor growth as compared to either reagent alone (Table 1 : exp. 1, Figure 
1С). However, in the second experiment, a reduction of tumor growth for this 
combination was found, compared with mAb G250 treatment alone. However, it 
should be noted that in this group only 4 mice were évaluable for antitumor response. 
Unfortunately, the antitumor effect of IFN-r/TNF-α was not determined in this 
experiment. In contrast, combination of mAb G250 with rIFN-a/rTNF-α demonstrated 
a significant reduction of mean tumor growth as compared to either mAb G250 
(p<0.001) or rIFN-a/rTNF-a (p<0.05) alone (Table 1, Figure ID). In both 
experiments, the combination of mAb G250 with rIFN-a/rTNF-α resulted in a better 
tumor growth inhibition as compared to the combination of mAb G250 with rlFN-
τ/rTNF-a. 
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42 Chapter II 
To exemplify the antitumor effects of this treatment, figure 2 shows individual 
growth curves of six individual tumors, treated with mAb G250 combined with rlFN-
a/rTNF-α. Of the initial ten tumors in this treatment group, one tumor did not 
respond to the treatment, and followed a growth curve similar to the slowest growing 
tumor in the control group. Immediately after treatment cessation, four mice, including 
the non-responder, were sacrified for analysis of tumor histology. The remaining six 
mice were further observed after termination of treatment. Two of these mice (no. 1 
and 2) developed progressively growing tumors within two weeks. In addition, mouse 
no. 3 developed a progressively growing tumor approximately one month after the 
treatment was ended. In contrast, two mice (no. 4 and 6) remained free of tumor, and 
no relapse was seen during a follow-up of three months after cessation of treatment. 
The slowly growing tumor of mouse no. 5 started to regress 30 days after treatment 
was stopped. Eventually all evidence of tumor disappeared (Fig. 2). 
1000 
800 
600 
400 
200 -
Tumor Size Index 
control 
alFN/TNF + G250(500) 
140 160 
Fig 2. Follow-up of tumor growth in 6 individual mice treated with mAb G250 combined with rlFN-
of/rTNF-α. Treatment was stopped on day 58. The mean tumor growth of the control group is given 
(n=10) up to 58 days as the animals had to be killed due to large tumor load. Data are presented 
from experiment 1. 
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Immunohistochemical analysis of RCC NU-12 tumors 
Representative tumor sections of the control groups showed that the RCC NU-12 
xenograft was mainly composed of large tumor cells of the clear cell type, similar to 
the morphology described (Beniers et al., 1992). The xenografts were surrounded by 
mouse stromal tissue that contained macrophages (Fig. ЗА) and were G250 antigen 
positive in line with earlier observations. 
Treatment of NU-12 tumors with rIFN-a/TNF-α, rlFN-r/TNF-o: or mAb G250 
alone did not result in any morphological alterations or in increased cellular 
infiltration. In contrast, immunohistochemical analysis of tumors from mice treated 
with rIFN-a/TNF-α and mAb G250 revealed an enhanced presence of macrophages, 
infiltrating the necrotic tumor areas (Fig. 3B). In some mice, no residual tumor cells 
were found. 
Fig 3 Immunohistochemical staining of tumor sections with mAb MAC-1 A untreated NU-12 
xenograft, В NU-12 xenograft, treated with mAb G250 in combination with rIFN-a/TNF-a 
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DISCUSSION 
The results of clinical trials with single cytokines in humans with advanced 
cancers have been disappointing for most tumor types, possibly due to dose-limiting 
toxicity without reaching effective doses (Rosenberg, 1989). In this respect it is 
promising that combination therapy in animal models has shown synergistic antitumor 
effects compared to single agent therapy (Baisch et ai, 1990; Beniers et ai, 1991α). 
These findings may be explained by different, mutually reinforcing mechanisms of 
antitumor activity for both cytokines used (Baisch et al., 1990). Monoclonal antibodies 
may offer additional means of stimulating the immune system to combat cancer, and 
they can also be used in combination with cytokines. 
In this study we investigated the effects of administration of mAb G250 on the 
tumor growth of established RCC NU-12 xenografts in nude mice. Furthermore, we 
investigated whether the growth retardation of fully established RCC NU-12 
xenografts by rIFN-a/rTNF-α or rIFN-r/rTNF-a could be enhanced by combination 
with mAb G250. Earlier we have shown that mAb G250 preferentially localizes in 
human RCC, and remains bound to tumor tissue sufficiently long to show therapeutic 
efficacy if mAb G250 had any intrinsic therapeutic capacity (Oosterwijk et aL, 1986; 
Van Dijk et al., 1991). 
We show here that mAb G250, IgG2a subclass, has significant antitumor effects 
when tested in the unmodified form in nude mice bearing established RCC tumors of 
30-50 mm3. Treatment with isotype matched control mAb did not result in tumor 
growth retardation. The antitumor effects of mAb G250 seemed to be Fc-receptor 
mediated: treatment of tumors with G250 F(ab')2 fragments did only result in a small 
tumor growth inhibition. In the present study an IgG2a subclass switch variant of the 
original mAb G250 was used, because the IgG2a isotype of mouse mAbs binds 
effectively to Fc-receptors of mouse immune cells (Johnson et aL, 1986; Steplewski 
et ai, 1991). In addition, little effect was observed when tumors were treated with 
mAb G250 IgG2b (unpublished observation). We therefore suggest that the tumor 
growth retardation with mAb G250 (IgG2a) alone is the result of induction of ADCC, 
in line with observations of other investigators (Adams et al., 1984; Buchsbaum étal., 
1992; Schreiber et ai, 1992). 
In this study we deliberately have chosen for treatment of established xenografts 
(30-50 mm3 in size) in order to mimic the human situation. Although treatment with 
mAb G250 did result in a significant tumor growth inhibition, complete tumor 
regression was not observed. As described in other studies where mAb treatment was 
the sole therapy, established tumors may be less responsive to mAb treatment as 
compared to mAb treatment initiated directly after tumor challenge (Schreiber et ai, 
1992). Nevertheless, studies have been described in which a single injection caused 
complete tumor regression of established tumor (Buchsbaum et al., 1992). 
Combination therapy of NU-12 tumors with mAb G250 and rIFN-a/TNF-a 
resulted in a significant increase of tumor growth inhibition compared to both 
treatments alone. The doses of cytokines used were based on earlier studies and have 
been shown to result in optimal tumor growth inhibition of established small RCC 
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NU-12 tumors (Beniers et al, 1991a). Interferons are known to be quite species-
specific, although some species cross-reactivity has been observed (Smith et al, 
1990). In contrast, rTNF-a shows significant species cross-reactivity with respect to 
mouse NK cell and monocyte/macrophage activation (Smith et al, 1990). 
Furthermore, we cannot exclude that part of the antitumor effects was mediated by 
direct effects on the NU-12 tumor cells. 
Activation of monocytes/macrophages induced by the rIFN-a/TNF-α treatment, 
may have resulted in increased ADCC by m Ab G250. rTNF-α has been shown to 
increase Fc7-receptors on peritoneal macrophages (Hoffman and Weinberg, 1987). As 
discussed earlier, it is likely that the antitumor effect of mAb G250 is mainly ADCC 
mediated. Because ADCC has been shown to be dependent on mAb density (Schreiber 
et al, 1992), enhanced mAb G250 targeting due to rIFN-a treatment, although not 
studied, may have played a role as well (Murray et al, 1990; Greiner et al., 1987). 
Treatment of RCC NU-12 xenografts with rlFN-r/rTNF-a and mAb G250 did 
not result in an enhanced antitumor effect as compared to both treatment schedules 
alone (Table 1, exp. 1). However, in the second experiment, in which treatment with 
mAb G250 alone was less effective than in the first experiment, the combination of 
mAb G250 with rIFN-r/rTNF-α was more effective than mAb G250 alone. 
Unfortunately, in this experiment the antitumor effect of treatment with rlFN-r/rTNF-
α could not be determined, because of insufficient number of tumor bearing mice in 
this group. Although it can not be excluded from our study that the combination of 
mAb G250 with rIFN-r/rTNF-α has significant anti tumor effects, compared with both 
treatments alone, the additive value of mAb G250 in this particular regimen is less 
than with rIFN-a/TNF-α in both experiments. This finding is comparable to 
observations with human melanoma xenografts treated with rlFN-r, rTNF-α and mAb 
(Gridley et al., 1989). Apparently rIFN-r/rTNF-α do not stimulate mouse 
monocytes/macrophages to that extent, as we suggested for rIFN-a/rTNF-α. Our 
results are in line with comparative in vivo studies that showed improved antitumor 
effects of rIFN-a compared to rIFN-r when combined with rTNF-a (Beniers et ai, 
1991a). 
Comparison of tumor biopsies obtained from different treatment groups revealed 
high numbers of macrophages and necrotic tumor cells with very little viable tumor 
cells in the mAb G250/rIFN-a/rTNF-a treatment group. This suggests that the 
macrophages are the effector cells responsible for the observed antitumor effects in 
our study. Other investigators have also observed the presence of enhanced 
macrophage infiltrates after treatment with cytokines or mAb (Adams et al., 1984; 
Balkwill et al, 1986; Baisch et al, 1990). With respect to RCC, high numbers of 
infiltrating macrophages are generally observed in the stromal compartment of RCC 
tumors. However, NK cells have also been shown to be effective in tumor growth 
control (Eisenthal et al, 1990). We have not investigated the presence of mouse NK 
cells in the NU-12 xenografts, and are therefore unable to assess the role of these cells 
in our study. 
Treatment of NU-12 xenografts with mAb G250 in combination with rTNF-
a/TNF-a resulted in complete tumor regression in several animals. In 2 mice, no 
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relapses were observed during follow-up of 3 months In addition, one tumor 
regressed 30 days after treatment cessation and disappeared completely, suggesting a 
late antitumor effect Anti-idiotypic responses against mAb G250 could induce such 
an antitumor effect Anti-idiotypic responses have been correlated with favourable 
outcome of therapy (Koprowski et al, 1984) Anti-idiotype antibodies bearing the 
internal image of mAb G250 might have been induced in the course of the repeated 
high dose mAb G250 injections 
In summary, we have shown that treatment of established human RCC xenografts 
with mAb G250, rIFN-a/rTNF-α, or rIFN-r/rTNF-a results in significant antitumor 
effects Combination of anti-RCC mAb G250 with rIFN-a/rTNF-α resulted in a 
significantly increased antitumor effect as compared to treatment with mAb G250 of 
rIFN-a/TNF-α alone, with several tumors in complete regression The observation of 
high numbers of infiltrating macrophages in the RCC xenografts, the known activation 
of these effector cells by cytokines, and the high number of infiltrating macrophages 
m tumors of RCC patients, suggests that a combination of cytokines and antitumor 
mAbs may have therapeutic value in the treatment of RCC 
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SUMMARY 
The potential usefulness of internal image anti-idiotype antibodies (Ab2s) to 
modulate hosts' immune responses to tumor-associated antigen (TAA) have stimulated 
considerable interest in the development and characterization of Ab2s. 
Six different mouse monoclonal Ab2s (NUH31, 44, 51, 71, 82 and 91) were 
generated against murine monoclonal antibody G250 (mAbG250) which recognizes a 
human renal cell carcinoma-associated antigen. All six Ab2s showed specificity for the 
mAbG250 paratope in Western blot analysis. In inhibition assays, all Ab2s were able 
to compete with the nominal antigen, albeit with different efficiency. Based on cross-
blocking studies for idiotope mapping, the Ab2s could be divided into two groups 
(groupl; NUH31, 51, 71, group2; NUH44, 82, 91). However, cross-reactivity 
between these two groups was observed, indicating that they recognized partly 
overlapping epitopes on the paratope of mAbG250. 
Sera from rabbits immunized with Ab2s showed reactivity with G250 antigen-
positive cell lysates, but not with antigen-negative cell lysates. Additional studies 
revealed that all Ab2s were able to induce anti-anti-idiotype antibodies resembling 
mAbG250 (АЬГ). These findings suggest that the Ab2s functionally mimic the 
original G250 antigen and that they might be of potential use for immunotherapy in 
human renal cell carcinoma. 
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INTRODUCTION 
According to Jerne's network theory, the immune system is at a steady state by 
an equilibrium of lymphocytic clones bearing complementary receptors (Jerne, 1974). 
This equilibrium can be disturbed either by external (foreign) or internal (self) antigen 
resulting in a response which aims at the restoration of the balance. In this response, 
anti-idiotype antibodies play a major role. Anti-idiotype antibodies (Ab2) elicited by 
the variable region of the inducing antibody (Abl) can be divided into three 
categories: 1) Ab2 recognizing an epitope in the binding site (paratope) of the idiotypic 
antibody, 2) Ab2 binding near the paratope of Abl and interfering with Abl-antigen 
interactions, 3) Ab2 structurally substituting for the nominal antigen recognized by 
Abl (so-called "internal imageH antibodies). Antibodies of the latter category offer 
promise as "vaccines" to various infectious agents (Sikorska, 1988) and they might be 
used to induce immune responses to tumor antigens (Ferrone, 1990; Robins, et al., 
1991). 
In renal cell carcinoma (RCC), the patients' immune system status seems to 
play a role in the disease course (De Riese, et al., 1991). Ritchie et al. (1984) have 
shown that untreated RCC patients have a deficit of Τ helper (Th) cells and abnormal 
Τ helper/T suppressor (Th/Ts) ratios. After removal of the primary tumor the Th cell 
levels increased, but with progression of the disease the Th cell deficit reappeared. De 
Kernion et al. (1979) described the decrease of antibodies against poorly defined TAA 
in advanced RCC patients with disease progression. These studies suggest that RCC 
patients raise an (abortive) immune response against their tumor. 
A number of RCC-associated antigens aberrantly expressed in RCC have been 
identified (E.g., Finstad, et al., 1985; Oosterwijk, étal., 1986; Vessella, étal., 1985). 
One of these RCC-associated antigens (antigen G250), identified by monoclonal 
antibody G250 (mAbG250) is expressed at high levels on the surface and in the 
cytoplasm of RCC cells from most RCC, whereas expression in normal tissues is 
restricted to cytoplasmatic expression in gastric mucosal cells and larger bile ducts 
(Oosterwijk, et al., 1986). Treatment of established RCC xenografts in nu/nu BALB/c 
mice with mAbG250 alone or in combination with cytokines resulted in complete 
tumor eradication (Van Dijk, et al., 1993). In some animals, tumor regression was 
observed after mAbG250 treatment was stopped, whereas tumors treated with 
cytokines alone started to grow as soon as treatment was ended. This late anti-tumor 
effect might be explained by the induction of internal image anti-idiotype antibodies, 
giving rise to anti-anti-idiotype antibodies (Ab3) resembling mAbG250 (АЬГ). Based 
on these results, we have started to produce anti-idiotype (internal image) mAbs raised 
against mAbG250. In the present study, we describe six anti-idiotype mAbs (NUH31, 
44, 51, 71, 82 and 91) which seem to resemble G250 antigen. These Ab2s might be 
useful as tumor-vaccines for RCC patients. 
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MATERIALS AND METHODS 
Chemicals 
All chemicals, control mouse immunogloblin (Ig), and anti-mouse antisera were 
obtained from Sigma Chemical Co, St Louis, MO. 
Animals 
8-week-old male BALB/c mice were used for the immunizations, 10-week-old 
BALB/c nu/nu mice were used for ascites production and 8-month-old New Zealand 
White (NZW) rabbits were used for anti-anti-idiotype antibody induction studies. 
Animals were purchased from the breeding unit of the University of Nijmegen, The 
Netherlands. 
Cells 
The human RCC cell lines SK-RC-52 and SK-RC-10, reactive with mAbG250, 
and SK-RC-59, non-reactive with mAbG250 were obtained from the Sloan-Kettering 
Institute, New York. Sp2/0 mouse myeloma cells were used for the fusions. Cells 
were cultured in RPMI 1640 medium supplemented with L-glutamine and 10% fetal 
calf serum. 
Monoclonal antibodies 
mAbG250, a murine monoclonal antibody which recognizes a RCC-associated 
antigen, was used to generate anti-idiotype mAbs. The isolation and characterization 
of mAbG250 has been described elsewhere (Oosterwijk, et al., 1986). The 
biochemical characterization of G250 antigen is incomplete, and we have not been able 
to purify the antigen to homogeneity. The antigen is heat-labile, susceptible to trypsin 
and pepsin digestion, neuraminidase and periodate resistant, and can be partly purified 
by hydrophobic column chromatography. The antigen is not present in lipid extracts 
of G250-positive cells or fresh RCC specimens (E.Oosterwijk, unpublished 
observations). These results indicate that mAb G250 recognizes a protein. 
Spontaneously arising isotype-switch-variants producing mAbG250 IgG2a 
immunoglobulin were isolated by limiting dilution and sib selection as described 
earlier (Van Dijk, et al., 1989). F(ab')2 fragments of mAbG250 IgGl and IgG2a were 
prepared by pepsin digestion. Mouse/human chimeric mAbG250 IgGl (cG250) was 
a gift from Dr. S. O. Warnaar, Centocor BV (Leiden, The Netherlands). Mouse 
myeloma protein MOPC-21 was used as an isotype-matched control. 
Immunization and Ab2 production 
mAbG250 IgGl was cross-linked with Keyhole-Limpets-Hemocyanin (KLH). 
Eight week-old male BALB/c mice were immunized i.p. with 50μg (100 μΐ) of 
mAbG250 IgGl cross-linked with KLH emulsified in an equal volume of complete 
Freund's adjuvant (CFA). Mice were boosted 3 times with the same amount of 
immunogen in incomplete Freund's adjuvant (IFA) at 3 week intervals. Before fusion, 
mice were boosted on 3 consecutive days and splenocytes were fused with Sp2/0 
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mouse myeloma cells on day 5 using standard methods. Hybridoma supernatants were 
screened by enzyme-linked immunosorbent assay (ELISA) for Ab2 production (see 
below). Cells of positive wells were cloned 3 times on soft agarose and further 
characterized. 
Detection of idiotype specific Ab2s by ELISA 
Hybridoma supernatants were tested for secretion of Ab2 reactive with 
mAbG250 IgGl F(ab')2 fragments, cG250 and/or mAbG250 IgG2a F(ab')2 fragments. 
Briefly, 96-wells microtiter plates (Becton Dickinson, Lincoln Park, NJ) were coated 
overnight at 4 °C with mAbG250 IgGl F(ab')2 fragments, cG250 or mAbG250 IgG2a 
F(ab')2 fragments (1 /zg/well) in 0.1 M carbonate buffer pH 9.6. Remaining binding 
sites were blocked with 1 % bovine serum albumin/phosphate-buffered saline 
(BSA/PBS) for 1 hr at room temperature. Wells were incubated with culture 
supernatants for 1 hr at room temperature, washed with BSA/PBS, incubated with goat 
anti-mouse Fc or goat anti-human Fc conjugated to horse radish peroxidase for Ihr, 
washed 3 times with BSA/PBS and developed with 100 /Л/well O-
phenylenediamine/0.03 % H202 for 20 minutes. The reaction was stopped with 50 
μΐ/well 2.5 M H2S04 and optical density was read at 492 nm. 
Preparation of cell lysates 
G250 antigen-positive (G250+) and G250-negative (G250) cells were washed 
twice with cold PBS and harvested. Approximately 1 g of cells in 10 ml PBS/0.5 % 
aprotinin was homogenized with a tissue homogenizer (Kinematica GmbH, Littau, 
Switzerland) and centriftiged at 13000 g for 15 minutes. The pellets were resuspended 
in 10 ml PBS/0.5 % aprotinin/0.3 % deoxycholate, homogenized with a tissue 
homogenizer and centriftiged at 13000 g for 15 minutes. The supernatants were stored 
at -20 °C and used for coating purposes. All procedures were done at 4 °C. 
Purification and radiolabeling of mAbs 
mAbs were purified from ascitic fluid by affinity chromatography on protein 
A-Sepharose, and radiolabeled with 125I by the chloramine-T method. 
Inhibition assay 
To determine the binding capacity of cell lysates, serial dilutions of G250+ cell 
lysates were dried on flexible 96-wells vinyl microtiter plates (Costar, Cambridge, 
MA) overnight at 37 °C. Remaining binding sites were blocked with BSA/PBS for 1 
hr and 100 μί of serial diluted 125I-labeled mAbG250 (125I-mAbG250) was added to the 
wells and incubated for 1 hr at room temperature. After washing 3 times with 
BSA/PBS, wells were cut and bound radioactivity was determined. The inhibition of 
binding of mAbG250 to G250+ cell lysates by Ab2s was tested as follows: 100 μί 125I-
mAbG250 was incubated with serial dilutions of hybridoma supernatants or with 
purified Ab2s for 45 minutes. The mixture was added to wells coated with G250+ cell 
lysates and incubated for 1 hr at room temperature. After washing, bound 123I-
mAbG250 was measured. The results were expressed as percent inhibition of binding 
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of 125I-mAbG250 to G250+ cell lysates. This radioimmunoassay (RIA) was also done 
using 125I-cG250. 
Determination of relative affinity constants 
The biologically non-reactive fraction of the radiolabeled Ab2s was determined 
by Lineweaver-Burk plots. For affinity determination, the equilibrium association 
constant was determined by Scatchard plots. Briefly, 96-well microtiter plates were 
coated with mAbG250 (1 μg/well) overnight at 4 °C. After blocking remaining protein 
binding sites with BS A/PBS, the wells were incubated with serial dilutions of 125I-
labeled Ab2s for 1 hr at room temperature, washed, and bound radioactivity was 
determined. 
Cross-blocking assay 
Microtiter plates were coated with mAbG250 (1 μg/well) overnight at 4 °C and 
the remaining protein binding sites were blocked with BS A/PBS. Thereafter wells 
were incubated for 1 hr at room temperature with serial dilutions of unlabeled Ab2. 
A fixed amount of 125I-labeled Ab2, corresponding to 50 % of the maximum binding 
to mAbG250 was added and incubated for Ihr at room temperature. The plates were 
washed 4 times with BSA/PBS and bound radioactivity was determined. The results 
were expressed as the percent binding of 125I-labeled Ab2 to mAbG250. 
SDS-PAGE and Western blotting 
mAbG250 IgGl, mAbG250 IgG2a F(ab')2 fragments and MOPC-21 IgGl were 
separated under reducing and non-reducing conditions on Polyacrylamide gels and 
transferred to nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany). 
After blocking remaining binding sites with 3 % BSA/PBS overnight at 4 °C, the blots 
were incubated with Ab2s (10 μg/ml) for 2 hr at room temperature. Following 3 
washes with 3 % skim-milk in PBS, the blots were incubated with 125I-mAbG250 for 
1 hr. After washing, the membranes were dried and autoradiography was performed 
using Kodak diagnostic film. After 1 day, films were developed in a Kodak X-OMAT 
developer (Kodak, Rochester, NY). 
Ab3 induction in rabbits 
NZW rabbits were immunized i.e. with 250 μg of purified Ab2s or MOPC-21, 
emulsified in CFA. The animals were boosted s.c. every three weeks with the same 
amount of immunogen in IFA. Blood was collected through the ear vein 10 days after 
each booster. In the present study sera taken after the third booster were investigated. 
The presence of Ab3 in rabbits was determined as follows: Microtiter plates 
coated with G250+ or G250 cell lysates were blocked with BSA/PBS and incubated 
with serial dilutions of Ab3 sera or pre-immune sera for 1 hr at room temperature. 
Following 3 washes, swine anti-rabbit IgG conjugated to horse radish peroxidase was 
added and incubated for 1 hr at room temperature. After 3 washes, the wells were 
developed with 3,3',5,5'-tetramethylbenzidin/0.03 % H202 for 15 minutes. The 
reaction was stopped with 2.5 M H2S04 and optical density was read at 450 nm. 
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Competitive assay of Abl and Ab3 
In order to remove non-specific anti-mouse reactivity, rabbit sera were 
preabsorbed with normal mouse IgG conjugated to Affigel 10 (Bio-Rad Laboratories, 
Richmond,С A). Microtiter plates coated with G250+ cell ly sates were blocked with 
BSA/PBS and incubated with 100 μΐ of serial dilutions of Ab3 antisera for Ihr at room 
temperature. A fixed amount of l25I-labeled mAbG250 or 125I-cG250 was added and 
incubated for 1 hr at room temperature. After 4 washes with BSA/PBS, bound 
radioactivity was determined. 
RESULTS 
Generation and characterization of Ab2s 
Immunization of mice with mAbG250 cross-linked with KLH and subsequent 
fusions of the mouse spleen cells with SP2/0 cells resulted in 20 wells with hybridoma 
cultures secreting Ig reacting with mAbG250 IgGl F(ab')2 fragments as well as cG250 
(IgGl). To investigate whether the secreted Ig's recognized the antigen binding site 
(paratope) of mAbG250 or an epitope outside the paratope of mAbG250 (e.g. the CH2 
region of IgGl), their reactivity with mAbG250 IgG2a F(ab')2 fragments was 
investigated. Ten hybridomas showed reactivity with F(ab')2 fragments prepared from 
both mAbG250 IgGl and IgG2a, whereas no reactivity was observed with isotype 
matched non-relevant IgGl. These ten hybridomas, designated NUH11, 21, 31, 44, 
51,61,71,82,91 and 102, were subcloned three times on low melting agarose. Nine 
mAb2s (NUH11-91) were further investigated. 
Since the possibility existed that these Ab2s recognized idiotopes present on the 
isolated heavy and light chain of mAbG250, i.e., represented non-internal image 
antibodies, Western blots of reduced and non-reduced mAbG250 IgGl and it's F(ab')2 
fragments, and MOPC-21 IgGl were reacted with the Ab2s. All nine Ab2s showed 
clear, unequivocal binding to non-reduced mAbG250 IgGl as well as mAbG250 
F(ab')2 fragments but not to control Ig (Fig. 1). No reactivity was seen with the 
isolated heavy and light chains of mAbG250 (results not shown). 
To define which Ab2s represented internal image antibodies, an inhibitory RIA 
was performed with purified mAbs NUH11-91, 125I-mAbG250 or 125I-cG250, and 
antigen positive cell lysates. For all Ab2s, (NUH11-91) a dose dependent inhibition 
of binding of 125I-mAbG250 to G250+ cell lysates was observed. However, the Ab2 
dose required to reach 50 % inhibition of maximum binding of 125I-mAbG250 to G250 
antigen differed (Fig. 2, Table 1). 
In the inhibitory RIA with 125I-cG250, same result was obtained for six Ab2s 
(NUH31, 44, 51,71, 82 and 91), but the remaining three Ab2s ( NUH11, 21 and 61) 
did not show inhibition of binding of 125I-cG250 to G250+ cell lysates, indicating that 
these three Ab2s did not present true internal image Ab2s. Six Ab2s were further 
investigated. 
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Because the differences observed in the inhibitory RIA might be due to different 
affinity constants (K
av
) of Ab2s to Abl, K
av
s were calculated by Scatchard analysis. 
These K
av
s were obtained for bivalent antibody, and therefore represent relative 1<ц 
values (Kaufman and Jain, 1992). The relative K
av
s of NUH31-91 ranged from 0.45 
to 1.25 X 1010 M l (Table 1) and no correlation was observed between K
av
 values and 
Ab2 doses needed to obtain 50% inhibition of ,25I-mAbG250 binding, indicating that 
individual differences between different Ab2s were not attributable to relative high or 
low Кз . 
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Fig. 1. Western blot analysis of Ab2s with mAbG250 on non-reduced SDS-PAGE. Lane a: MOPC-
21, Lane b: mAbG250 IgGl, Lane c: mAbG250 F(ab')2 IgG2a. A: Coomassie Brilliant Blue stained 
gel, B: autoradiogram of Western blot incubated with NUH71, C: autoradiogram of Western blot 
incubated with NUH91. 
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Fig. 2. Inhibition of mAbG250 binding to antigen-positive (G250+) cell Iysates by Ab2s. Mixtures 
of l25I-mAbG250 or ,25I-cG250 and serial diluted Ab2s or MOPC-2L were added to wells coated with 
G250+ cell Iysates. After 1 hr incubation, plates were washed with BS A/PBS and bound radioactivity 
was measured. Results are expressed as percent inhibition of l25I-cG250 binding to G250+ cell Iysates. 
The values shown are averages of triplicate assays. 
Table. 1. CHARACTERIZATION OF ANTI-IDIOTYPE ANTIBODIES 
Name 
of Ab2 
NUH31 
NUH44 
NUH51 
NUH71 
NUH82 
NUH91 
Subclass 
igGl 
lgG2a 
lgG1 
lgG1 
IgGl 
IgGl 
Affinity binding 
constant to АЫ 
(x10,0M') 
1.18 
1.25 
0.45 
1.25 
0.82 
1.08 
50% inhibition of 
АЫ binding to Ag 
Ab2 cone (.g/ml) 
0.94 
0.42 
0.84 
0.67 
0.35 
0.51 
Table 1. Relative affinity of Ab2s to mAbG250 was determined as follows; first the biologically non-
reactive fraction of ,25I-Ab2s was determined by Lineweaver-Burk plots. To determine equilibrium 
constants, serial dilutions of ,25I-Ab2s were added to wells coated with mAbG250 (1 /xg/well) over 
night at 4 °C. After washes, bound 125I-Ab2s were measured and affinity constants were determined 
by Scatchard plots. 
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Fig. 3. Cross-blocking assay to define the spatial relationsh'p of the idiotopes recognized by each 
Ab2 Wells coated with mAbG250 (1 /ig/well), blocked with BSA/PBS, were incubated with serial 
dilutions of unlabeled Ab2s A fixed amount of ,25I Ab2, corresponding to 50 % of the maximum 
binding to mAbG250 was added and incubated for 1 hr After washes with BSA/PBS, bound 
radioactivity was determined The results are expressed as percent binding of l25I-Ab2 to mAbG250 
The values shown are averages of triplicate assays Here, one of nine cross-blocking experiments 
(with l25I-NUH71) is shown Similar experiments with l25I labeled NUH31, 44, 51, 82 and 91, 
showed the same results 
61 
Induction and characterization of АЬЗ 
To examine whether NUH31-91 could induce Ab3s that mimic mAbG250 
(АЬГ), i.e., represent functional internal image antibodies, NZW rabbits were 
immunized with Ab2 or MOPC-21 Ig. In direct ELISA, pre-immune sera did not show 
any reactivity with G250+ or G250 cell lysates (results not shown), whereas the post-
immune sera of rabbits immunized with NUH31, 44, 51, 71, 82, and NUH91 showed 
a dose dependent reaction with G250+ cell lysates (Fig. 4A) in comparison to G250 
cell lysates (Fig. 4B). Serum of the rabbit immunized with MOPC-21, did not show 
any reactivity with G250+ cell lysates. All immune sera, including serum obtained 
from the MOPC-21 immunized rabbit, showed a slight increase of reactivity with the 
G250 cell lysates compared to the pre-immune sera (results not shown). 
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Fig. 4. Detection of anti-anti-idiotype antibody (АЬГ) in rabbit sera Microtiter plates were coated 
with G250-positive (A) and G250-negative cell lysates (B) and incubated with serial dilutions of АЬЗ 
sera obtained from the rabbits immunized with NUH31, 44, 51, 71, 82 or 91 After washes with 
BSA/PBS, bound АЬЗ was detected with swine anti-rabbit IgG conjugated to horse radish peroxidase 
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Fig. 5. Competitive assay of Abl and Ab3 to antigen-positive (G250+) cell lysates. Sera from the 
rabbits immunized with NUH31, 44, 51, 71, 82 or 91 were preabsorbed with mouse IgG. Microtiter 
plates coated with G250+ cell lysates were incubated with serial dilutions of Ab3 sera pre-absorbed 
with mouse serum. A fixed amount of ,25I-mAbG250 or l25I-cG250 was added and incubated for Ihr. 
After washes, bound radioactivity was determined. Results are expressed as percent inhibition of l 2 5I-
cG250 binding to G250* cell lysate. The values shown are averages of triplicate assays. 
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DISCUSSION 
Current interest in the idiotypic network stems from the potential use of anti-
idiotype antibodies as (tumor) vaccines. Immunization with an Ab2 may result in 
tumor immunity, since the original tumor epitope and the hypervariable region of the 
Ab2 can have immunologic identity. Initially, tumor vaccines consisted of autologous 
tumor cells and different vaccination strategies have been applied with variable results. 
In RCC, Tykkä et al. (1978) treated stage III and IV patients with polymerized 
autologous tumor cells after palliative nephrectomy and reported a significant 
improvement of survival in comparison with patients not receiving immunotherapy. 
However, other investigators were unable to demonstrate any effect of autologous 
tumor vaccination in RCC patients (Fowler, 1986). 
Vaccines existing of mAbs bearing the internal image of a tumor-associated 
antigen (TAA) may provide new therapeutic modalities. They offer the advantages of 
being a pure and abundant supply of the immunogen, possibly being more 
immunogenic than the original tumor antigen. In recent years, several investigators 
have developed anti-idiotype antibodies mimicking TAA of different tumor types 
defined by corresponding Abls i.e., "internal image Ab2s" (Barth, et al., 1989; 
Kusama, et al., 1989; Warren and Tsang, 1990; Chattopadhyay, et al., 1991; Gaida, 
et al., 1992). In animal models Ab2 vaccination has been shown to result in Ab Γ 
induction despite expression of the corresponding antigen in normal tissue, whereas 
immunization with antigen-positive cells did not result in Ab Γ induction 
(Chattopadhyay, et al., 1991). In a clinical trial with Ab2s resembling a melanoma-
associated antigen, a significant increase in survival of high staged melanoma patients 
was observed (Mittelman, et al., 1990; Chen, et al., 1992), and vaccination with Ab2 
105AD7 resembling gp72 antigen, initially identified in osteosarcomas, induced tumor-
specific humoral as well as cellular responses in patients with colorectal cancer 
(Robins, et al., 1991; Durrant, et al., 1993). 
RCC seems to be particularly suited for anti-Id treatment: the host's immune 
system seems to play a role in the disease course (Ritchie, et al., 1984; De Riese, et 
al., 1991); a number of unique RCC-associated antigens have been described that may 
be candidate target molecules (E.g., Vessella, et al., 1985; Finstad, et al., 1985); and 
current therapies for disseminated RCC are largely ineffective (Strohmeyer and 
Ackermann, 1991), emphasizing the need for new therapeutic approaches. 
In the present study, we describe the isolation and characterization of internal 
image mAbs resembling RCC-associated G250 antigen. This antigen is homogeneously 
expressed in a high percentage of RCC and its expression on normal tissues is 
restricted to normal gastric mucosa and cells of the larger bile ducts (Oosterwijk, et 
al. 1986). Nine Ab2s (NUH11, 21, 31, 44, 51, 61, 71, 82 and 91) were isolated that 
reacted with mAbG250 IgGl and IgG2a F(ab')2 indicating that they reacted with the 
variable region of mAbG250 and not with a constant region. These nine Ab2s also 
bound to mAbG250 separated under non-reducing conditions, but not under reducing 
conditions, suggesting that the epitope(s) recognized by NUH11-91 resided in or close 
to the binding pocket of mAbG250, and might resemble internal image antibodies. 
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By definition, internal image antibodies need to be able to compete with the 
nominal antigen. All nine Ab2s showed a dose dependent inhibition of binding of 125I-
mAbG250 to antigen. However three Ab2s (NUH11, 21 and 61) were unable to 
inhibit C-G250/G250 antigen binding. Apparently, these Ab2s recognize an epitope 
close to the epitope that defines the internal image of mAbG250, resulting in 
disturbance of mAbG250-G250 antigen interaction. The other six Ab2s (NUH31, 44, 
51, 71, 82 and 91) showed identical results with cG250. 
The remaining six Ab2s were not equally effective in inhibitory RIA. These 
differences could be due to different K
av
s for an identical binding site, or, 
alternatively, some Ab2s represented true internal image antibodies, whereas others 
recognized (a) spatially closely located (partly overlapping) epitope(s), resulting in less 
efficient competition. Binding of the latter antibodies will interfere with Abl-Ag 
interactions. Determination of relative K
av
 values did not indicate that the observed 
inhibitory differences could be explained by different K
av
 values. We therefore 
performed cross-blocking assays to determine the spatial relationship of the NUH31-91 
epitopes. Based on these experiments, the six Ab2s could be divided into two groups: 
NUH31, 51 and 71 versus NUH44, 82 and 91. Remarkably, each Ab2 was able to 
inhibit binding of all other Ab2s, albeit less efficient. It is therefore likely that two 
different, partly overlapping idiotopes on mAbG250 are recognized. 
To investigate which Ab2 was able to induce Ab3 functionally resembling Abl 
(АЬГ), NZW rabbits were immunized with purified IgGs. NUH31, 44 and 91 elicited 
Ab3 sera that reacted strongly with G250+ cell lysates but not with G250" cell lysates. 
NUH51, 71 and 82 immunized rabbits produced sera of lower titers. In a competitive 
assay also designed to test for АЬГ, similar inhibition of ,25I-mAbG250 and Ab3 
interaction was observed for all six Ab2s. The discordance between these two tests can 
be explained as follows: in a competitive RIA, Ab3s induced by Ab2s partly 
resembling Abl mAbG250 will be less effective competitors than АЬГ induced by 
true internal image Ab2s. However, the former Ab3s will bind as well as true АЬГ 
in the direct ELISA. It is likely that the results of the competitive RIA are a more 
appropriate reflection of the presence of АЬГ. In this view, immunization of NZW 
rabbits with NUH31, 44, 51, 71, 82, or 91 resulted in АЬГ, with NUH44 showing 
the most favorable internal image Ab2 characteristics. 
The differential inhibition of mAbG250-G250 antigen binding by different Ab3 
sera might be a reflection of subtle differences between the anti-idiotypic epitopes 
recognized by NUH31-91. These subtle differences will result in some sera containing 
Ig that reacts with determinants different from the determinant defined by mAbG250, 
with less efficient inhibition of mAbG250-G250 antigen binding. 
Antisera from the rabbits immunized with NUH11, 21 and 61 failed to show 
clear competition with 125I-mAbG250 and also failed to bind with cG250, confirming 
that these Ab2s are not true internal image antibodies (data not shown). 
We noticed unequal АЬГ induction by Ab2s as judged in competitive RIA from 
the two groups that seem to define (partly) overlapping epitopes on mAbG250. 
Likewise, Ab2s from both groups showed comparable АЬГ induction (e.g. NUH44 
and 91), indicating that Ab2s from both groups functionally resemble the nominal 
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G250 antigen, i.e., are immunologically identical to Abl. These observations can be 
explained if complete structural mimicry of the nominal G250 antigen is not required 
for Ab Γ induction as was suggested by Kohler et al. (1989). 
The unequal Ab Г induction can also be explained by poor immunogenicity. 
Lehmann et al. (1992) reported that Ab Г induction may vary, and vaccination with 
otherwise undistinguishable internal image Ab2s may not result in Ab Г production, 
suggesting that subtle differences between internal image Ab2s exists (Chattopadhyay, 
et al , 1991) Alternatively, unmodified anti-idiotype mouse IgG may be poorly 
immunogenic. Ab Γ development can be improved by immunization with Ab2-KLH 
conjugates and subsequent mixing with FA (Chen, et al , 1993). 
Although G250 antigen is expressed in rabbits similar to humans: large bile 
ducts and gastric mucosal cells are G250+ (Oosterwijk, unpublished observations), all 
six Ab2s induced АЬГ in NZW rabbits. I.e. a specific anti-tumor-associated antigen 
G250 response was elicited by this vaccination. This is similar to the observations of 
Chattopadhyay et al (1991) who reported the induction of АЬГ against a melanoma-
associated antigen which is expressed in some normal rabbit tissues. Apparently, 
antigen expression in a restricted number of normal tissues does not compromise the 
induction of АЬГ. Considering the similarity of G250 antigen expression in human 
and rabbits, active specific immunotherapy of RCC patients with these Ab2s 
representing the nominal RCC-associated antigen G250 may therefore result in similar 
specific anti-tumor response. We are currently investigating which Ab2 is the best 
clinical candidate for active specific immunotherapy of RCC patients. 
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SUMMARY 
We have previously isolated and characterized 6 anti-idiotype antibodies (Ab2s) 
directed against monoclonal antibody G250 (MAbG250) which reacts with a tumor-
associated antigen (TAA) expressed in a large proportion of human renal cell 
carcinoma (RCC). These 6 Ab2s (NUH31, 51, 71, 82, 91: IgGl, NUH44: IgG2a) 
showed MAbG250 binding site specificity and induction of anti-TAA antibody 
resembling MAbG250 (so-called АЬГ) in rabbits, indicating that they are internal 
image antibodies. 
To investigate whether these Ab2s could induce G250-TAA specific cell 
mediated immunity, delayed-type hypersensitivity (DTH) test were carried out with 
G250 antigen-positive and/or -negative cells in the ears of BALB/c mice. Mice primed 
with Ab2 showed antigen specific DTH responses, whereas no significant DTH 
response was observed with G250-negative cells. This antigen specific DTH could be 
transferred to naive mice by lymphocytes harvested from Ab2 sensitized mice. In 
addition to the classical DTH responses observed 24 and 48 hr after tumor challenge, 
an early phase antigen specific hypersensitivity response was seen 2 hr after challenge. 
This early component of the specific hypersensitivity reaction but not the classical 
DTH could be transferred to naive mice by serum from Ab2 sensitized mice, 
indicating that the early reaction was due to serum factors. These findings demonstrate 
that all Ab2s induced tumor specific cellular immune responses directed against human 
RCC, and suggest that they may be useful as RCC-TAA surrogates, i.e., as tumor 
vaccines for RCC patients. 
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INTRODUCTION 
There is clinical as well as experimental evidence that the disease course of 
renal cell carcinoma (RCC) is influenced by tumor specific cellular and humoral 
immune responses (De Kernion, et al., 1979; Ritchie, et al., 1984; Ritchie and De 
Kernion, 1987; De Riese, et al., 1991). Untreated RCC patients have a deficit of Τ 
helper (TH) cells that disappears after surgery and reappears with tumor recurrence 
(Ritchie, et al., 1984), the serum titer of poorly defined anti-RCC antibodies fluctuates 
and correlates with the tumor load (De Kernion, et al., 1979). In addition, numerous 
spontaneous regressions have been documented (De Riese, et ai, 1991), and the 
disease may reappear after being dormant for more than a decade (Ritchie and De 
Kernion, 1987), indicating that some RCC patients mount an (abortive) RCC-specific 
cellular response (Alexander, et al., 1990; Finke, et al., 1992). In general, current 
therapies for (disseminated) RCC lack efficacy. In some patients treatment with 
biological response modifiers with or without lymphocyte transfer was remarkably 
effective, but for the majority of RCC patients these treatments are ineffective. 
Therefore, the development of new, more effective therapeutic agents is needed. 
The idiotypes (Id) of an antibody, defined as the collections of antigenic 
determinants of an antibody, play a major role in the immune response (Jeme, 1974). 
Anti-Id antibodies (Ab2s) mimicking nominal antigens, so called internal image Ab2s, 
are of particular interest, since these might function as idiotype vaccines and may be 
able to elicit specific immune responses (Ferrone, 1990; Nisonoff, 1991). Ab2 
immunization of patients with malignant melanoma and colorectal cancer has shown 
that internal image Ab2s can substitute for tumor-associated antigens (TAA), as 
evidenced by tumor specific humoral and cellular immune responses (Mittelman, et 
ai, 1990, 1992; Durrant, et ai, 1993). Because such Ab2s are able to elicit specific 
anti-tumor immune responses, they show promise as new therapeutic agents. 
We have previously described six internal image monoclonal anti-Id antibodies 
(NUH31, 44, 51, 71, 82 and 91) directed against the paratope of anti-RCC antibody 
MAbG250 (Uemura, et al, 1994). Immunization of rabbits with these Ab2s induced 
anti-anti-Id antibodies (Ab3) resembling the initial anti-tumor antibody MAbG250 
(Abl), showing that the Ab2s truly behaved as internal image antibodies, i.e., 
immunologically, these Ab2s mimic the nominal G250 antigen. In the present study, 
we investigated whether immunization with the Ab2s resulted in tumor specific cellular 
immune responses. For this purpose, mice were immunized with Ab2s, subsequently 
challenged with G250 antigen-positive (G250+) and G250 antigen-negative (G250 ) 
RCC cells and delayed type hypersensitivity tests were performed. 
MATERIAL AND METHODS 
Animals and cells 
Eight to 10 weeks old female BALB/c mice were purchased from the breeding 
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facility of the University of Nijmegen, The Netherlands. Mice were maintained on a 
standard diet and water adlibitum. 
The human RCC cell lines SK-RC-52 (G250 antigen positive, G250+) and SK-
RC-59 (G250 antigen negative, G250") were used for tumor challenges. The 
characteristics of SK-RC-52 and SK-RC-59 have been described elsewhere (Eben el 
al., 1990). Cells were cultured in RPMI 1640 medium (GIBCO, Grand Island, NY) 
supplemented with 10% fetal calf serum and 2 mM L-glutamine. 
Monoclonal antibodies 
MAbG250, a murine monoclonal antibody which recognizes a RCC-associated 
antigen expressed in the majority of RCC, was used to generate anti-idiotype MAbs. 
The characterization of MAbG250 has been described elsewhere (Oosterwijk, et al., 
1986). Murine anti-idiotype monoclonal antibodies, NUH31, 51, 71 and NUH44, 82 
and 91 which define two different, overlapping antigenic determinants in the paratope 
of MAbG250 (Uemura, el a/., 1994), were used to sensitize mice. Immunoglobulins 
were purified from mouse ascites fluid by protein A chromatography. Mouse myeloma 
protein MOPC-21 (Sigma, St Louis, MO) was used as an isotype-matched control. 
Sensitization 
Ab2s were cross-linked with Keyhole-Limpets-Hemocyanin (KLH, Sigma) 
according to Bona et al. (1979). Mice were immunized s.c. with 50μg (100 μ\) of each 
Ab2 cross-linked with KLH emulsified in an equal volume of complete Freund's 
adjuvant (CFA, Sigma). Mice were boosted twice by intraperitoneal injections with 
the same amount of immunogen in incomplete Freund's adjuvant (IFA, Sigma) at 2 
week intervals. Seven days after the last booster, their cellular immune responses were 
tested in a delayed-type hypersensitivity assay. 
Delayed-type hypersensitivity assays 
Delayed-type hypersensitivity (DTH) reactions were measured by the ear 
swelling assay. A dose of 2.5 χ 105 viable SK-RC-52 (G250+) cells in 0.01 ml PBS 
was injected intradermally into the pinna of the right ear and the same number of SK-
RC-59 (G250) cells was injected into the left ear pinna of sensitized and non-
sensitized mice. Ear thickness was measured before, 2, 6, 24 and 48 hr after 
challenge, using a micrometer (TESA, Renens Switzerland) by two independent 
observers who had no knowledge of the sensitization of the mice. The differences 
between the ear swelling in sensitized mice and non-sensitized mice was calculated and 
expressed as specific ear swelling (s.e.s.) (Vandebriel, el ai, 1989). 
Serum and lymphocyte transfer 
Immunized mice were sacrificed seven days after the last immunization and 
serum, spleens, and draining lymph nodes were harvested. Single cell suspensions of 
spleens and lymph nodes were prepared by squeezing the tissues through a 300/лп 
metal sieve followed by a 40-70 mesh nylon filter. After centrifugation (5 minutes, 
400g) and resuspension of the cell pellet, cell number and viability were determined. 
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To determine whether the DTH response could be transferred, serum (0.2 ml) 
or lymphocytes (107 /0.4 ml normal saline) were injected intravenously into the tail 
vein of naive BALB/c mice 30 minutes before tumor cell challenge. 
Statistical analysis 
Groups of five mice were used and each experiment was performed at least 
twice. The difference between groups was analyzed using the Student-t test; ρ < 0.05 
was chosen as a significant difference. 
RESULTS 
Induction and specificity of delayed-type hypersensitivity response 
To assess whether TAA G250 specific cellular mediated immune responses 
could be induced by anti-Id MAbs NUH31, 44, 51, 71, 82, and 91, BALB/c mice 
were immunized and subsequently challenged with G250+ and G250 human RCC 
cells. Representative results of the DTH reactions observed in these mice are presented 
in figure 1. Clearly, immunization with any of the six Ab2s resulted in cellular 
mediated immune responses as judged by the strong DTH reactions. As shown by the 
absence of DTH reactions to G250" cells, the strong DTH reactions was TAA G250 
specific (G250+ versus G250": NUH31, 44, 51, 82, 91; p<0.01, NUH71; p<0.05). 
Immunization with irrelevant antibody did not induce cellular immune responses: 
challenge with neither G250+ nor G250' cells resulted in DTH responses (MOPC-21 
versus all NUH; ρ < 0.05), indicating that the DTH reactions observed with NUH31, 
44, 51, 71, 82, and 91 were not due to non-specific cellular responses induced by 
immunization with mouse IgG cross-linked to KLH. 
The six Ab2 were equally effective in inducing cellular immune responses as 
the strength and duration of the DTH reactions of animals immunized with different 
Ab2s were very similar. 
The G250-specific DTH reactions demonstrated biphasic patterns with an early 
(2 hr) and late (classical) phase (24 and 48 hr; Fig. 1). Both early and late reactions 
were Ab2 specific as immunization with irrelevant IgG did not result in any response 
(MOPC-21 versus NUH; p<0.05). At all time points the differences between 
challenge with G250+ and G250" cells was highly significant (p<0.01), with the 
exception of 6 hours after tumor challenge where no DTH reaction was observed in 
any group. 
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Fig. 1. Specificity of DTH responses to G250+ (A) and G250 (B) cells in Ab2s-sensitized BALB/c 
mice. Groups of five BALB/c mice were immunized with Ab2 or MOPC-21 conjugated to KLH in 
CFA. After 2 boosters, 5 χ IO4 cells were injected into the ear pinna. The increase of ear thickness 
was measured 2, 6, 24 and 48 hrs after tumor challenge. The ear swelling is expressed as s e.s. χ IO3 
mm (see Material and Methods). *: p<0.01, **: p<0.05, challenge with G250+ cells versus 
challenge with G250 cells. 
DTH induced by lymphocyte transfer 
The DTH reactions of naive animals that were challenged with G250+ and 
G250" cells after receiving lymphocytes harvested from immunized mice are presented 
in figure 2. These lymphocyte transfers resulted in transmittance of both the early and 
the classical DTH responses against G250 antigen-positive cells (Fig. 2). Profound 
specific· DTH reactions were present 2, 24 and 48 hours after tumor cell challenge. 
The strength as well as the time course of the DTH reactions that resulted from these 
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lymphocyte transfers were similar to those observed in immunized animals (compare 
figures 1 and 2). No differences were observed between DTH reactions elicited by 
different anti-Id M Abs. 
The early as well as the late DTH responses elicited by cell transfer were 
antigen specific as challenge with G250" cells did not result in any DTH response (for 
ρ values see Fig. 2). Lymphocytes harvested from mice sensitized with irrelevant 
mouse IgG MOPC-21 were not able to induce a DTH response. The DTH reactions 
induced by transferral of lymphocytes harvested from Ab2 immunized animals 
compared to MOPC-21 immunized animals were significantly higher (NUH51, 71, 82, 
91; p<0.01, NUH31, 44; p<0.05, 24 hours after tumor challenge). Similar to the 
DTH reactions observed in immunized animals, no significant reaction was seen 6 hr 
after tumor challenge. 
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Fig. 2. DTH responses to G250+ (A) and G250 (B) cells in naive mice that received 2 χ IO7 
lymphocytes harvested from sensitized mice. Animals were divided into groups of five animals and 
30 min. after the lymphocytes transfer» 5 xlO4 antigen-positive and -negative cells were injected into 
the ear pinna and DTH responses were measured 2, 6, 24 and 48 hrs after challenge. The increment 
of ear thickness is expressed in s.e.s. χ IO3 mm. *: p<0.01, **: p<0.05, challenge with G250+ 
cells versus challenge with G250 cells. 
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DTH induced by serum transfer 
To investigate whether the early DTH response depended on circulating serum 
factors, serum transfer experiments were performed with immune serum harvested 
from mice immunized with any of the six Ab2. Figure 3 shows that the early 
component of the DTH reaction was transferable to naive animals: challenge with 
G250+ and G250 cells after receiving serum from animals that had been immunized 
7 days earlier resulted in the occurrence of DTH reactions to G250+ cells similar to 
the reactions seen in sensitized animals (compare figures 1 and 3) whereas challenge 
with G250" cells did not induce any response (NUH71, 82; ρ < 0.01, NUH31, 44, 51, 
91; ρ<0.05). The late, classical DTH response was completely absent. Transfer of 
serum collected from animals immunized with irrelevant IgG did not induce a DTH 
response. Serum obtained three weeks after the last Ab2 immunization was also 
ineffective in eliciting an early DTH response in naive mice (data not shown). 
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Fig. 3. Hypersensitivity responses to G250* (A) and G250 (B) cells in serum transferred mice. Naive 
BALB/c mice (n=5) received lv injections of 0.2 ml serum obtained from the six Ab2 immunized 
mice 30 min before tumor challenge. The increase of ear thickness was measured 2, 6, 24 and 48 hrs 
after challenge, and expressed in s e s. χ ΙΟ'3 mm. *. p<0.01, **: p<0.05, challenge with G250+ 
cells versus challenge with G250 cells. 
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DISCUSSION 
The fundamental goal of vaccination of cancer patients is the induction of tumor 
immunity to prevent tumor recurrence and to eliminate residual disease. However, 
spontaneously arising tumors tend to be poorly immunogenic compared to tumors 
induced by carcinogens or viruses. Because TAA are also found on spontaneously 
arising tumors, this lack of immunogenicity has been thought to reflect either self-
tolerance as the result of lack of tumor specificity of the TAA (Lennox, 1983), or 
genetic low responsiveness of the host (Lilly, et al., 1964). Down-regulation of МНС 
molecules on tumor cells and loss of TAA are other possible mechanisms of tumor 
immune evasion. A number of investigators have shown that Ab2 functionally 
mimicking the nominal antigen recognized by Abl, can induce antigen specific cellular 
and humoral immune responses (Dunn, et al, 1987; Austin, et al, 1991; Chen, et 
al, 1991; Durrant, et al, 1992). Apparently presentation of the nominal antigen in 
another context is sufficient to produce anti-tumor immune responses. Thus, such 
Ab2s hold promise as idiotype vaccines (Sikorska, 1988). 
The present study investigated the induction of cellular immune responses to 
anti-Id M Abs mimicking the RCC-associated antigen G250. We have previously 
shown that the six Ab2s used in the present study were able to induce antigen specific 
humoral immune responses in rabbits (Uemura, et al, 1994). In this report we 
demonstrate that these six Ab2s can induce TAA specific cellular immune responses 
against RCC cells. Challenge of mice immunized with NUH31, 44, 51, 71, 82 or 91 
with G250+ cells resulted in a profound DTH reaction, whereas no DTH reaction was 
observed with G250 cells. Mice immunized with control IgG did not show any DTH 
reaction, indicating that the DTH reaction of the Ab2 immunized animals was TAA 
related, and not due to immune responses induced by the immunization of mouse IgG 
cross-linked to KLH. 
Induction of cellular mediated immunity against syngeneic and non-syngeneic 
tumors by Ab2s has been investigated in a number of tumor types (Dunn, et al., 1987; 
Raychaudhuri, et ai, 1987a; Austin, étal, 1991; Chen, étal, 1991; Durrant, étal, 
1992). For example, immunization of mice with Ab2 mimicking the human high-
molecular-weight melanoma-associated antigen (Chen, et al, 1991) or a TAA 
expressed on the majority of colorectal cancers (Austin, et al, 1991) induced DTH 
reactions comparable to our observations. 
In addition to the classical DTH response that was observed 24 and 48 hr after 
tumor challenge, an earlier antigen-specific reaction was seen. This early reaction 
could be transferred to naive mice by lymphocytes as well as serum from sensitized 
mice, whereas serum transfer never resulted in classical DTH, indicating that serum 
factors were responsible for this early reaction. Several investigators have shown that 
soluble antigen-specific T-cell factors (TCF), i.e., antigen-specific products of T-
lymphocytes, can provide antigen-specificity to non-specific cells (Vandebriel, et al, 
1989; Van Loveren, et al, 1985). Vandebriel et al. investigated two TCF in an 
allogenic tumor system and demonstrated that both TCF were antigen specific, able 
to induce an early DTH response, and unable to induce the classical DTH response. 
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The circulation of these factors was restricted to the first days after immunization 
(Vandebriel, et aL, 1989). Our results strongly suggest that immunization with the 
anti-Id M Abs resulted in the production of similar T-lymphocyte dependent factor(s): 
the early DTH reaction was antigen specific, transferable by immune serum, and 
restricted to serum harvested soon after immunization. The observation that 
lymphocyte transfer also resulted in the induction of early G250-specific reactions 
indicates that it is likely that substantial amounts of these factors were produced. 
Based on cross-blocking assays we have been able to divide the six Ab2s into 
two groups that seem to define two partly overlapping epitopes (NUH31, 51, 71 
versus NUH44, 82, 91). However, despite subtle differences, all Ab2 could induce 
Ab3 resembling Abl, indicating that complete structural mimicry of the nominal G250 
antigen was not required (Uemura, et al.4 1994). Similarly, despite subtle differences 
between the Ab2s, all Ab2s were equally effective in the induction of DTH. No 
significant differences in the strength and length of the DTH response were observed. 
Apparently all six Ab2s present G250 a specific epitope(s), regardless of their different 
fine specificities. 
Several investigators have shown that some RCC patients mount an (abortive) 
RCC-specific cellular response (Alexander, et ai, 1990; Finke, et al.y 1992). 
However, these patients still succumb to their disease, i.e., the cellular immune 
response is ineffective with respect to protection against tumor recurrences and in 
combatting the primary tumor. Considering the evidence that RCC is influenced by 
(abortive) cellular and humoral immune responses, RCC-TAA may be poorly 
immunogenic. Recently, Kündig et al. (1993) described that the immunogenicity of an 
artificial TAA depended upon the context in which the TAA was presented and 
concluded that even a weakly priming vaccine may lead to tumor elimination. The 
present study and our previous results indicate that immunization with the Ab2s 
mimicking TAA G250 results in tumor specific cellular and humoral immune 
responses (Uemura, et ai, 1994) and therefore these Ab2s may function as effective 
anti-tumor vaccines. Other investigators have shown that Ab2 vaccination can result 
in rejection of tumor challenge or tumor growth inhibition (Dunn, et я/., 1987; 
Raychaudhuri, et ai, 1987b; Powell, et ai, 1989) and Ab2 immunization of cancer 
patients induced tumor-binding Ab3 (Mittelman, et al.y 1992). In conclusion, it 
appears that Ab2 mimicking TAA, like the internal image anti-Id used here, may be 
able to function as effective anti-tumor vaccines. 
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SUMMARY 
We have previously isolated and characterized six different internal image 
mouse monoclonal anti-idiotype antibodies (Ab2) directed against the paratope of 
mouse monoclonal antibody G250 (MAbG250, Abl) which specifically reacts with 
human renal cell carcinoma (RCC). These Ab2s (NUH31, 44, 51, 71, 82 and 91) 
demonstrated specificity for the combining site of Abl, and appeared to recognize two 
partly overlapping idiotopes on Abl. In this study, we further characterized the fine 
specificity of the Ab2, investigated whether the immunogenicity of Ab2 could be 
enhanced by conjugation to a carrier, and investigated the anti-tumor efficacy of Ab3 
sera in mice challenged with RCC. 
Immunization of animals with Ab2 conjugated to keyhole limpets hemocyanin 
as carrier protein resulted in a twofold increase in antigen-specific anti-anti-idiotype 
antibodies (Ab3) as compared to immunization with Ab2 alone. Specific reactivity was 
observed with antigen positive cell lysates, and all Ab3 sera contained immunoglobulin 
resembling Abl (АЬГ), as shown by competitive Abl-antigen binding assays. Fine 
specificity studies of Ab3 sera revealed that the Ab2s can be divided into four 
mutually exclusive groups: 1) NUH31 and 51, 11) NUH44 and 82, 111) NUH71, IV) 
NUH91, showing that the six Ab2s recognize four slightly different idiotopes in the 
Abl binding pocket. Treatment of RCC-challenged mice with Ab3 sera resulted in 
significant tumor growth inhibition (p<0.01) and lower tumor-take rates as compared 
to control groups. Ab3 sera obtained from NUH-91 immunized animals showed 
superior characteristics as compared to the other Ab3 sera. These findings demonstrate 
that these Ab2 induce specific humoral responses against RCC and that they elicit 
powerful anti-tumor effects in immune competent animals. This suggests that these 
Ab2s might be useful as tumor vaccines in RCC patients. 
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INTRODUCTION 
Anti-idiotype antibodies (Ab2) recognize antigenic determinants present on other 
antibody molecules (Jerne, 1974). Ab2 bearing the internal image of the nominal 
antigen (so-called internal image antibodies) which functionally mimic the nominal 
antigen might be useful as vaccines, e.g., to combat viral infections and malignancies. 
It has been shown that Ab2 vaccination can induce tumor-associated antigen (TAA) 
immunity and can result in tumor rejection in animal systems (Nepon, et al., 1984; 
Lee, et al., 1985; Dunn, et al, 1987; Powell, et al., 1989). Recently, several 
investigators have investigated the effects of Ab2 vaccination in melanoma and 
colorectal cancer patients (Mittelman, et al., 1990; Adler, et al., 1993; Herlyn, et al., 
1987; Durrant, et al., 1993). Mittelman et al. immunized melanoma patients with a 
mouse Ab2 that bear the internal image of the high-molecular-weight melanoma-
associated antigen (HMW-MAA). In 60% of Ab2 vaccinated patients, anti-HMW-
MAA antibodies could be detected, with a statistically significant prolongation of their 
survival (Mittelman, et ah, 1992). Adler et al. (1993) evaluated the effects of Ab2 
MELIMMUNE™-2 alone or Ab2 mixed with adjuvant, and demonstrated that Ab2 
plus adjuvant resulted in a significant higher titer of antibodies resembling the initial 
Abi (AbΓ antibodies). In colorectal cancer, advanced stage patients were treated with 
a human Ab2 which resulted in a significant improvement in survival of Ab2 
vaccinated patients (Durrant, et al., 1993). The results obtained in these trials indicate 
that internal image Ab2 may represent new therapeutic agents. 
We have previously isolated and characterized six internal image anti-idiotype 
(anti-Id) monoclonal antibodies (MAbs), NUH31, 44, 51, 71, 82 and 91 (Uemura, et 
al., 1994a), directed against the binding site of a murine monoclonal antibody G250 
(MAbG250) which reacts with a large proportion of human renal cell carcinoma 
(RCC) (Osterwijk, et al., 1986). The TAA recognized by MAbG250 (G250) is 
expressed specifically and homogeneously on RCC cells. Expression on normal human 
tissues is restricted to gastric mucosal cells and large bile ducts (Oosterwijk, et al., 
1986). We have shown that the Ab2s functionally mimic the nominal antigen G250 
since immunization of mice and rabbits results in anti-anti-idiotype antibodies 
resembling the initial anti-tumor antibody MAbG250 (АЬГ). Cross-blocking RI As 
performed to investigate the spatial relationship between the idiotopes recognized by 
the six Ab2s revealed that they recognized different but partly overlapping idiotopes 
(Uemura, et al., 1994a). We have also shown that these Ab2s induce G250 specific 
cellular immune responses (Uemura, et al., 1994b). 
The goal of anti-idiotype vaccination is the induction of tumor immunity to 
prevent tumor recurrence and to eliminate residual disease. It is therefore crucial to 
identify Ab2 with an optimal immunological profile, i.e. with superior anti-tumor 
characteristics. Our previous investigations seemed to indicate that the six Ab2s 
represented potential therapeutic reagents for RCC patients. To further investigate the 
potential usefulness of these Ab2s, we studied whether the immunogenicity of the 
Ab2s could be enhanced by conjugation to a carrier; performed fine specificity studies 
of Ab3 sera to investigate subtle differences between Ab2; investigated whether Ab2 
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immunization induced anti-tumor immunity; and investigated whether these Ab2s 
exhibited different antitumor efficacy. 
MATERIAL AND METHODS 
Animals 
6- to 8-week-old female BALB/c mice, 6-week-old female BALB/c nu/nu mice 
and 10-month-old New Zealand White rabbits were purchased from the breeding 
facility of the University of Nijmegen, The Netherlands. 
Tumors 
SK-RC-52 is a G250 antigen positive (G250+) human renal cell carcinoma cell 
line, SK-RC-59 is G250. The cahracteristics of these cell lines have been described 
previously (Ebert et al, 1990). Cells were cultured in RPMI 1640 medium (GIBCO, 
Grand Island, NY) supplemented with 10% fetal calf serum and L-glutamine. 
Monoclonal antibodies 
M AbG250 is a murine monoclonal antibody which recognizes a RCC-associated 
antigen and specifically reacts with a large proportion of RCC (Oosterwijk, et al., 
1986). Chimeric MAbG250 (IgGl) was kindly provided by Dr. S.O. Warnaar 
(Centocor, Leiden, The Netherlands). The characterization of MAbG250 has been 
described elsewhere (Oosterwijk, et al., 1986). NUH31, 44, 51, 71, 82 and 91, 
internal image anti-Id MAbs directed against MAbG250 have been described and 
characterized previously (Uemura, et al., 1994a). Immunoglobulins were purified from 
mouse ascitic fluid by protein A chromatography. Mouse myeloma protein MOPC-21 
(Sigma, St Louis, MO) was used as an isotype-matched control. 
Ab3 antisera preparation 
BALB/c mice were immunized i.p. with any of the Ab2s or MOPC21 
conjugated to Keyhole Limpets Hemocyanin (KLH, Sigma, St Louis, MO) emulsified 
with complete Freund's adjuvant (CFA) and subsequently boosted with the same 
amount of immunogen emulsified with incomplete Freund's adjuvant (IFA) every three 
weeks. Seven to ten days after the third booster, sera were harvested. 
NZW rabbits were immunized s.c. with either Ab2 or Ab2 conjugated to KLH 
emulsified with CFA, and subsequently boosted with the same amount of immunogen 
emulsified with IFA at three week intervals. Sera were harvested two weeks after each 
booster. 
Serological assays 
In order to reduce interfering irrelevant anti-mouse Ig responses, rabbit sera 
were depleted from rabbit anti-mouse Ig by affinity chromatography on Affigel 10 
(Bio-Rad, Richmond, CA) coupled to non-specific mouse IgG. The binding capacity 
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of АЬЗ sera to antigen-positive cell lysates was determined by ELISA as described 
previously (Uemura, et al., 1994a). Briefly, wells of 96-well flat-bottom microtiter 
plates were coated with G250+ or G250 cell lysates or covered with G250+ or G250" 
cells. Cell lysate coated wells were blocked with 1 % BS A/PBS whereas G250+ and 
G250' cells were fixed with paraformaldehyde for 5 minutes, washed and blocked with 
1 % BS A/PBS. Thereafter, wells were incubated with serial dilutions of rabbit antisera 
for 1 hr at room temperature. After 3 washes, swine anti-rabbit IgG conjugated to 
horse radish peroxidase (Dako, Glostrup, Denmark) was added and incubated for 1 
hr at room temperature. After 3 washes, the wells were developed with 3,3',5,5'-
tetramethylbenzidin/0.03 % H202 for 15 minutes. The reaction was stopped with 2.5 
M H2S04 and optical density was read at 450 nm. To investigate whether АЬЗ sera 
contained Ig that could functionally substitute for Abl, i.e., whether Ab Г were 
present, competitive assays with I25I-cG250 and АЬЗ sera were carried out as described 
previously (Uemura, et al., 1994a). Briefly, microtiter plates coated with G250+ cell 
lysates or fixed with G250+ cells were blocked with BS A/PBS and incubated with 100 
μ\ of serial dilutions of АЬЗ antisera for Ihr at room temperature. A fixed amount of 
125I-labeled l25I-cG250 was added and incubated for 1 hr at room temperature. After 
4 washes with BSA/PBS, bound radioactivity was determined. 
Specificity of АЬЗ antisera 
The fine specificity of Ab2s was investigated by competitive RIA with 125I-
cG250 and АЬЗ sera as competitors for binding to Ab2, and inhibition RIA were 
performed with 125I-Ab2s, АЬЗ sera and MAbG250 F(ab')2. In competitive assays, 96-
well round-bottom polyvinyl chloride microtiter plates coated with any of the Ab2s 
(O^g/well) were blocked with 1 % BSA/PBS for 1 hr and incubated with a mixture 
of a fixed amount of 125I-cG250 and serial dilutions of АЬЗ sera for 1 hr at room 
temperature. After washing the plates four times with 1 % BSA/PBS, bound 125I-
cG250 was determined. The results were expressed as the percent inhibition of binding 
of 125I-cG250. In inhibition assays, microtiter plates coated with MAbG250 F(ab')2 
fragments were incubated with a fixed amount of any of the 125I-Ab2s and serial 
dilutions of АЬЗ sera for 1 hr at room temperature. After four washes, bound 125I-Ab2 
was measured. 
Protection experiments 
Groups of 5-6 female BALB/c nu/nu mice were injected s.c. with IO5 SK-RC-
52 cells, the minimum number of cells necessary to achieve 100 % tumor take. At the 
same time, treatment was started: Group 1 received serum obtained from mice 
immunized with NUH31-KLH (Ab3-31), Group 2 received serum from NUH71-KLH 
immunized mice (Ab3-71), Group 3 received serum from NUH82-KLH immunized 
mice (АЬЗ-82), and Group 4 received serum from NUH91-KLH immunized mice 
(Ab3-91). In control animals, no treatment was given (Group 5, None), animals 
received serum from MOPC21 immunized mice (Group 6, АЬЗ-MOPC) or received 
serum from non-immunized mice (Group 7, NMS), respectively. Mice received i.p. 
injections of 200 μΐ АЬЗ serum 3 times a week during 5 weeks. Each tumor was 
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measured twice a week with sliding digital calliper (Mitsutoyo, U.K.)· Tumor volume 
was expressed as the Tumor Size Index (T.S.I.) and calculated by the following 
formula: 
T.S.L(mm3) = L χ W χ Η /2 
where L, W and Η represent maximum length, diameter at right angles to the length, 
and thickness, respectively. After 8 weeks, mice were sacrificed and, if possible, 
tumors were harvested. 
Statistical analysis 
Groups of 5-6 mice were used and each experiment was performed at least 
twice. The difference between groups was analyzed using the Student-t test; ρ < 0.05 
was chosen as a significant difference. 
RESULTS 
Induction of АЫ' in rabbits and effects of carrier protein (KLH) 
We have previously shown that immunization with the Ab2 studied here 
induced anti-anti-Id antibodies resembling Abl (АЬГ) in rabbits (Uemura, et al., 
1994a). However the АЬГ titers remained moderate: serum dilutions necessary to 
achieve 50% of maximum antigen binding in binding ELIS As reached approximately 
1:300. To investigate whether higher АЬГ titers could be induced by conjugation of 
Ab2 to a carrier-protein, rabbits were immunized with Ab2-KLH or Ab2. In figure 
1 the titers necessary to achieve 50% of maximum binding in antigen binding ELISA 
are presented. After the first immunization, АЬГ could be detected in all sera, albeit 
at very low titers. The АЬГ titer of the antisera increased dramatically after the 
second booster, and achieved a maximum level after the fourth booster. The titer of 
the antisera obtained from the rabbits immunized with Ab2-KLH was considerably 
higher than that from the rabbits immunized with Ab2 alone (compare Fig. 1A to IB). 
MOPC21-KLH Ab3 sera did not show any reactivity with G250+ or G250 cell lysates 
or cell lines. In all experiments reported below, sera from animals immunized with 
Ab2-KLHs or MOPC21-KLH were used. Unabsorbed rabbit sera showed similar 
antigen-binding properties as absorbed Ab3 rabbit sera. Because cell lysates may yield 
non-specific binding of antibodies, Ab3 binding assays were also performed on 
paraformaldehyde fixed RCC cells. Identical results were obtained using these intact 
tumor cells. From a practical point of view, the use of cell lysates was preferable. 
Therefore, the majority of Ab3 binding assays were performed with cell lysates. 
However, tumor cell binding assays were also performed in parallel. There was 
always complete agreement between the results obtained with cell lysates and intact 
tumor cells. 
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Fig 1. АЬГ titers of rabbit sera obtained after Ab2 immunization (1A) or Ab2-KLH 
immunization (IB). Arrows indicate immunization. Sera were harvested 2 weeks after each 
immunization. Results are expressed as serum dilutions necessary to reach 50 % of maximum antigen 
binding. Curves represent averages from two individual rabbit sera for each immunization group. 
Each value represents the average of triplicates. 
Competitive RIA 
The results of competitive RIA with 125I-cG250 and Ab3 antisera, performed 
to confirm the presence of АЬГ in Ab3 rabbit sera, are presented in figure 2. All Ab3 
sera showed a dose dependent inhibition of binding of 125I-cG250 to G250+ cell lysates 
or G250+ cells, whereas sera from the rabbits immunized with MOPC21 or 
preimmune sera did not show any inhibition. The inhibitory capacity of sera obtained 
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from Ab2-KLH immunized rabbits was much higher than the capacity of sera 
harvested from Ab2 immunized rabbits (compare Fig. 2A and B). Notably, complete 
inhibition of ,25I-cG250-antigen binding could be achieved with 1:50 diluted Ab2-KLH 
induced sera, whereas the maximum inhibition with Ab2 induced sera reached 
approximately 60%. This indicates that Ab2-KLH immunization resulted in 
considerably higher АЬГ titers. No inhibition was observed when mAb RC38, was 
used as mAbG250-G250 antigen competitor. RC38 recognizes a gpl60 present on the 
majority of RCC (Oosterwijk et aly 1986). Competitive RIA with 125I-cG250 and 
unabsorbed rabbit sera showed identical results. However, at lower antisera dilutions, 
less competition was visible due to complexing of 125I-cG250, which still contains 
mouse encoded regions, and rabbit-anti-mouse immunoglobulin. 
50 100 200 400 Θ00 50 100 200 400 800 
antisera dilution 
Fig 2. Competitive RIA with i25I-cG250 and Ab3 rabbit sera obtained 2 weeks after the fourth 
booster from rabbits immunized with Ab2 alone (A) or Ab2-KLH (B). Antigen coated plates were 
incubated with a fixed amount of 125I-cG250 and serial dilutions of Ab3 sera. After washing 4 times, 
bound radioactivity was measured. Results are expressed as percent inhibition of binding of 123I-cG250 
to antigen-positive cell lysates. Values represent averages of triplicates. 
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Specificity of АЬГ 
To investigate whether subtle differences between Ab3 sera existed (possibly 
reflecting subtle differences between Ab2 specificities), fine specificity studies of Ab3 
sera obtained from rabbits and mice were performed. Although all Ab2 induce 
antibodies able to compete with Abl (Uemura, et al., 1994, this manuscript) they may 
induce different АЬГ subsets. Provided that their respective idiotopes are sufficiently 
far apart, the interference of different subsets of АЬГ with Abl-Ab2 binding can then 
be due to interference on different sites in the Abl binding pocket. Competitive RIA 
of Ab3 sera and 125I-cMAbG250 with individual Ab2s demonstrated that the six Ab2s 
could be divided into 4 mutually exclusive groups (Fig. 3). NUH71 and NUH91 
immunization resulted in Ab3 sera (Ab3-71, Ab3-91) with exquisite specificity for the 
respective Ab2: Abl-Ab2 binding could only be inhibited when the corresponding Ab2 
was present as binding moiety, but not when other Ab2 were present as inhibitor (Fig. 
3D, F). The remaining Ab3 sera could be divided into 2 groups: Ab3-31 and -51, and 
Ab3-44 and -82. Ab3-31 bound equally well to NUH51 (Fig. ЗА), and Ab3-44 to 
NUH82 (Fig. 3B), and vice versa (Fig. 3C, E). Similar results were obtained in 
inhibition RIA with 125I-Ab2s and Ab3 sera as inhibitors for binding to MAbG250 
F(ab')2 (results not shown). The six Ab2s could be divided into four groups regardless 
of the origin of the Ab3 sera (rabbits or mice). 
Therapeutic effects of Ab3 sera 
To investigate whether Ab2 vaccination resulted in tumor immunity, i.e., 
whether vaccination induced anti-tumor effects, mice were challenged with RCC cells 
and subsequently treated with Ab3 sera. The Ab3 sera were obtained from 4 Ab2s, 
representative for the 4 groups identified (Ab3-31, 71, 82 and 91). Four weeks after 
tumor cell challenge, small tumors were evident in all mice (Table 1). However, the 
tumor volumes in Ab3-31, -71, -82 and -91 treated animals were significantly lower 
as compared to control animals (p<0.05, Fig. 4 and Table 1). 
Eight weeks after tumor injection, i.e., three weeks after cessation of treatment, 
complete tumor regression was observed in all mice treated with Ab3-91, in one 
mouse treated with Ab3-31, and in two mice treated with Ab3-82. Although not all 
the tumors regressed completely, all tumors in АЬЗ-NUH treated groups showed 
significant inhibition of tumor growth (p<0.01 versus controls for all Ab3-NUH 
groups). Ab3-31 treatment seemed to result in tumor stabilization, whereas Ab3-71 
and 82 treatment resulted in slowly growing tumors with substantially decreased tumor 
doubling times as compared to non-treated tumors. In contrast, non-treated mice and 
mice treated with normal mouse serum or serum obtained from mice immunized with 
MOPC21-KLH showed normal tumor growth and 100 % tumor take (Fig. 4 and table 
1). Comparisons of tumor remnants showed identical. 
To investigate whether the differential anti-tumor effects could be attributed to 
differences in АЬГ titer, АЬГ titers were determined in direct antigen binding 
ELISA. No differences between the four Ab3 sera was observed. However, АЬГ 
titers were very low: the average titer to achieve 50 % of maximum binding to G250+ 
cell lysates was between 1:25 and 1:50 (results not shown). 
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Table 1. Summary of one representative protection experiment 
Treatment 
1 Ab3-31 
2 Ab3-71 
3 Ab3-82 
4 Ab3-91 
5 None' 
6 Ab3-MOPC 
7 NMS2 
8 MAbG250 
No of 
mice 
5 
5 
6 
6 
6 
6 
5 
6 
'None no treatment, : 
significali differnces, 
2NMS 
Tumor take (%) 
4w 
100 
100 
100 
100 
100 
100 
100 
100 
8w 
80 
100 
66 7 
0 
100 
100 
100 
100 
normal mouse serum 
* p < 0 0 1 , * * p < 0 05 
Tumor volume (mm3±SE) 
4w 
9 8±2 5* 
10±2 2* 
8 1±2 7* 
7 7±2 2* 
23 5±4 4 
29±7 5 
31 8 ± 1 4 4 
22 2±10 1 
8w 
11 8±5 6** 
26 7±5 2** 
17 9 + 8 7** 
o** 
126±16 6 
98 9±12 3 
114±21 0 
81 7±24 7 
Table 1. Tumor-take rates and tumor volume in animals treated with Ab3 sera and challenged 
with RCC cells. Mice were injected s с with IO5 SK-RC-52 cells and at the same time treatment with 
Ab3 sera was initiated Animals received 3 ι ρ injections weekly for 5 weeks In control animals no 
treatment was given, mice were treated with serum from MOPC21 immunized mice, or treatment 
consisted of injections with normal mouse serum Tumor volumes are expressed as mean ± SE 
* p < 0 05 compared to all controls, ** p < 0 01 compared to all controls 
DISCUSSION 
Renal cell carcinoma (RCC) is characterized by a number of unique biological 
features which seem to indicate that the immune system plays a role in the disease 
course: spontaneous regressions of metastatic disease are infrequently observed (De 
Riese, et al., 1991), Th cell deficits disappear after surgery and reappear with disease 
progression (Ritchie, et al., 1984), TAA-related antibodies circulate in RCC patients 
(deKermon, et al., 1979), and tumors may remain dormant for more than 10 years 
(Ritchie and deKernion, 1987). Conventional therapeutic strategies, i.e., radiotherapy, 
hormonal therapy and chemotherapy, are not effective for disseminated RCC (Graham, 
1989). Initially, encouraging result were obtained with active specific immunization 
with autologous tumor cell preparations after palliative nephrectomy (Tykka, et al., 
1978), but more extensive studies were unable to demonstrate any therapeutic effect 
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(Sahasrabudhe, et al., 1986; Fowler, et al., 1986; Schärfe, et al., 1989). The 
availability of biological response modifiers (BRM) such as interferons, interleukins 
and tumor necrosis factor, has spurred interest in their use as new immunotherapeutic 
modalities for RCC. The best results have been obtained by Rosenberg et al. (1989) 
who reported a 30% response rate in IL-2 treated patients. Clearly there is a need to 
develop new therapeutic modalities for this disease. 
A number of investigators have demonstrated that Ab2s functionally mimicking 
the original antigens recognized by Abls, can induce specific immune responses (e.g., 
Austine, et al., 1989; Barth, et al., 1989; Kusama, et al., 1989; Warren and Tsang, 
1990; Chattopadhyay, et al., 1991; Gaida, et al., 1992). Such Ab2s may represent 
new therapeutic modalities for cancer treatment, provided appropriate target antigens 
can be identified (Sikorska, 1988). However, despite intensive efforts, unique tumor-
specific antigens have not been identified for human tumors, and Ab2 resembling 
tumor-associated antigens (TAA) seem to represent the best candidates. Chattopadhyay 
et al. (1991) have shown that vaccination with Ab2 resembling the High-Molecular-
Weight Melanoma-associated antigen (HMW-MAA), that is also expressed on normal 
tissues, can induce HMW-MAA specific immune responses, indicating that TAA 
expression on a restricted number of tissues does not hamper the successful 
implementation of Ab2 vaccination. Ab2 vaccination may also provide several 
advantages over immunization with e.g. vaccination with autologous tumor cells: if 
monoclonal Ab2 are produced one has an unlimited supply of Ab2 with defined 
specificity, and Ab2 may be more immunogenic than the corresponding TAA due to 
different presentation of the TAA to the immune system. Based on the previous 
considerations, vaccination with Ab2 bearing the internal image of a TAA seems to 
represent an attractive approach in cancer immunotherapy. 
In accordance with our previous study (Uemura, et al., 1994a), immunization 
with any of the Ab2 resulted in the occurrence of Ab Γ antibodies, confirming that 
these Ab2 represent internal image Ab2. Conjugation of the Ab2 to KLH and 
emulsification in Freund's adjuvant resulted in a two-fold increase of АЬГ titers as 
compared to immunization with Ab2 alone. Chen et al. (1993) observed a similar 
increase in antibody titers. In their study the combined use of an adjuvant and a carrier 
enhanced the immunogenicity of Ab2 in rabbits more than each individually: anti-TAA 
antibodies were detectable in all rabbits immunized with Ab2-KLH mixed with FA, 
whereas only one of three rabbits immunized with Ab2 mixed with FA showed anti-
TAA responses and no anti-TAA could be detected in rabbits immunized with Ab2 or 
Ab2-KLH without FA (Chen, et al., 1993). In clinical trials, Ab2 manipulation also 
resulted in increased immunogenicity (Mittelman, et al., 1992; Adler, et al., 1993; 
Durrant, et al., 1993). However, concurrent mild adjuvant-related toxicity may limit 
their clinical use (Mittelman, et al., 1992; Alter, et al., 1993). 
Comparison of АЬГ sera of differently immunized animals did not reveal any 
differences between the sera other than the АЬГ titers. The increase in АЬГ titer was 
seen for all Ab2 and was observed in all animals immunized with Ab2-KLH/Freund's 
adjuvant immunized animals. As mentioned above, immunization with Ab2 resembling 
HMW-MAA did not always result in АЬГ antibody production (Chen, et al., 1993). 
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In the present study, Ab2 immunization alone was sufficient to elicit Abl' in all 
rabbits examined, indicating that the G250-related Ab2 are much more immunogenic 
than the HMW-MAA-related Ab2 studied by Chen et al. (1993). The different number 
of normal tissues expressing the respective antigens, HMW-MAA is more wide spread 
than G250 antigen, may play a role in the immunogenicity of the Ab2 investigated. 
In previous studies we have shown that the six Ab2 investigated recognize at 
least two partly overlapping idiotopes on MAbG250. Nevertheless, all Ab2 induced 
АЬГ as judged by the ability of Ab3 sera to interfere with Abl/Ab2 binding (Uemura, 
et al., 1994a). However, we were not able to exclude that Ab2s within one group 
were recognizing idiotopes in very close vicinity, because steric hinderence would 
mask the other idiotope in our cross-blocking assay. Because these subtle differences 
might be reflected in Ab3 sera containing Ab2-specific АЬГ, fine specificity studies 
of Ab3 sera were performed. In competitive RIA with Ab3 and 125I-cG250 competing 
for Ab2 binding, and by inhibitory RIA where binding of Ab3 sera to MAbG250 
F(ab')2 was inhibited by individual 125I-NUHs, the 6 Ab2s could be divided into 4 
mutually exclusive groups. Ab3-71 and Ab3-91 contained antibodies specifically 
reactive with unique idiotopes on NUH71 and NUH91 respectively whereas Ab3-
31/Ab3-51 and Ab3-44/Ab3-82 contained antibodies specifically reactive with two 
different idiotopes. These results indicate that the members of these four groups 
recognize four slightly different idiotopes in the binding pocket of MAbG250. Since 
they seem to recognize unique idiotopes in the MAbG250 binding pocket it implies 
that not all NUH are true representations of G250 antigen. Consequently, the Ab2 that 
is a perfect image of the TAA G250 may possess superior anti-tumor characteristics. 
The former grouping of the Ab2 by competitive binding of Ab2 to Abl is 
partially reflected in the Ab3 sera. By crossblocking assay, NUH31, 51, and 71 
appeared to recognize the same idiotope. Indeed, NUH31 and NUH51 induced 
undistinguishable Ab3. However, NUH71 vaccination resulted in unique Ab3. It it 
therefore likely that NUH71 recognizes an idiotope in close proximity of the 
NUH31/51 idiotope. Similarly, NUH44, 82, and 91 were part of one cross-blocking 
group (Uemura et al., 1994a). These three Ab2 could also be divided into two 
mutually exclusive groups: NUH44/82 versus NUH91. Again, these Ab2 probably 
recognize two different idiotopes. The seeming discrepancy between the cross-blocking 
assay and Ab3 inhibition assay can be explained by assuming close vicinity of these 
respective idiotopes, which would be distinguishable by cross-blocking assay (see 
above). Our results indicate that 4 different idiotopes are present within MAbG250 
paratope. 
To investigate the anti-tumor efficacy of immunization with Ab2, serum of 
immunized mice was transferred to nu/nu BALB/c mice injected with human RCC 
cells. Transfer of any NUH-АЬЗ resulted in significant tumor growth inhibition (4 
weeks; ρ < 0.05 for all groups, 8 weeks; ρ < 0.01 for all groups) and lower tumor take 
as compared to control groups. Four weeks after tumor challenge no significant 
differences between Ab3 treatment groups was seen. Small tumors were detectable in 
all АЬЗ-NUH treated animals. However, eight weeks after tumor challenge (three 
weeks after cessation of therapy), remarkable differences between the different 
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treatment groups were observed. All mice treated with Ab3-91 showed complete tumor 
regression. Macroscopically as well as microscopically no tumor remnants could be 
detected. Histologically, Ab3-31 treatment resulted in tumor regression in more than 
half of the animals and tumor stabilization of the remaining animals. Similarly, Ab3-
82 treatment effectuated tumor regression in more than half of the animals, with 
extremely slow growing tumors in the remaining animals. After Ab3-71 treatment 
slow growing tumors were measurable in all animals. The tumor doubling time was 
significantly lengthened in all Ab3 treated animals with remaining tumor. Three weeks 
after cessation of therapy the tumors started to grow with tumor doubling times 
comparable to control tumors. It is likely that three weeks after discontinuation of 
therapy the circulating levels of Ab Γ antibody and serum factors were depleted and 
too low for continuation of tumor control. Likewise, the early growth of the tumors 
treated with Ab3-91 can be explained by a dose effect. Because the АЬГ titers were 
moderate, a number of treatments may be necessary to achieve sufficient high levels 
of АЬГ for tumor control and regression. Based on these results we conclude that 
NUH-91 immunization elicits the most powerful anti-tumor effects, and that this Ab2 
might be the best candidate for clinical trials. 
Since the animals were treated with whole serum, we cannot discriminate 
between АЬГ anti-tumor effects and anti-tumor effects by circulating serum factors, 
e.g., Τ cell factors and cytokines. We and others have shown that combination therapy 
with biological response modifiers (BRMs), part of serum circulating factors, can 
result in significant tumor growth inhibition. Complete tumor control of freshly 
inoculated RCC tumors could be achieved only when a very intense IFNa/TNFa 
dosing schedule (3 times/wk IFNa, 5 times/wk TNFa, peritumoral injections), was 
followed. It is highly unlikely that Ab3 sera contained TNF/IFN levels comparable to 
the TNF/IFN levels given in the former study (Beniers, et ai, 1991). Therefore, it 
is hard to conceive that the anti-tumor effects of Ab3 sera are solely due to circulating 
BRMs. 
Τ cell factors such as Specific Macrophage Arming Factor (SMAF) and Mast 
cell T-Cell Factor (MTCF) can, amongst others, provide antigen-specificity to non­
specific cells, e.g., macrophages which are powerful mediators of cell lysis (e.g., 
Van Loveren, et al., 1985; Vandebriel, et al., 1989; Parmentier, et al., 1991). We 
have shown that immunization with any of the six Ab2 investigated results in profound 
transferable early DTH responses, attributable to TCF factors (Uemura, et al., 1994b, 
and submitted for publication). Because these factors persist approximately 2-16 days 
after immunization (Vandebriel, et al., 1989), and animals were treated with immune 
serum harvested 7-10 days after immunization, we cannot exclude that part of our 
observed anti-tumor effects are attributable to TCF. In a syngeneic system, successful 
vaccination against the tumor did not require the production of high titers of АЬГ 
(Dunn et al., 1987), emphasizing the importance of cell mediated immunity. However, 
increased survival of patients after Ab2 vaccination has been correlated with АЬГ 
occurence (Mittelman et al., 1992). In agreement with studies emphasizing the 
importance of cellular immunity, increased survival after Ab2 vaccination has also 
been observed in the absence of АЬГ (Durrant et al., 1993). Immunization with 
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purified MAbG250 (Abl) resulted in tumor growth inhibition, but no complete tumor 
control (results not shown) Therefore it is likely that TCF played a role in the tumor 
regression with Ab3-NUH91 Although it is important to identify the effectiveness of 
each component, it is more important to identify Ab2 with therapeutic efficacy 
In summary, NUH-31, -44, -51, -71, -82, and -91 immunization induced 
RCC-TAA G250 specific humoral responses The immunogenicity of these Ab2s could 
be enhanced by conjugation to a carrier, and vaccination with any of the Ab2 elicited 
powerful anti-tumor effects NUH-91 seems to represent the best candidate for clinical 
studies, since NUH-91 immunization resulted in complete tumor regression 
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SUMMARY 
We have shown that six different internal image anti-idiotype antibodies (Ab2) 
raised against the combining site of MAbG250 (Abl) which specifically reacts with 
a human renal cell carcinoma (RCC)-associated antigen, induce antigen specific 
humoral and cellular responses in mice. These 6 Ab2 can be divided into four 
mutually exclusive groups: I) NUH-31 and -51, II) NUH-44 and 82, III) NUH-71, IV) 
NUH-91. Immunization with NUH82 or NUH91 resulted in Ab3 sera that gave 
complete protection against tumor challenge. In this study, we tested the anti-tumor 
efficacy of NUH82 and NUH91 induced mouse sera (Ab3 sera; Ab3-82 and Ab3-91) 
in mice with established subcutaneous human RCC xenografts. 
Mice were treated 3 times a week by i.p. injection of 0.2 ml Ab3 sera or 250 
/tg MAbG250/ 0.2ml PBS for 6 weeks. Treatment of NU12 human RCC xenografts 
of approximately 20 mm3 expressed as tumor size index (T. S. I.) with NUH-АЬЗ sera 
or MAbG250 resulted in significant tumor growth inhibition as compared to tumors 
treated with Ab3 sera from mice immunized with control immunoglobulin (Ab3-
MOPC). In all АЬЗ-NUH treated mice, tumors stabilized or disappeared completely. 
In contrast, Ab3-MOPC treatment did not result in any anti-tumor effects. Tumor 
remnants in АЬЗ-NUH treated animals contained viable tumor cells surrounded by 
infiltrating mouse cells, whereas no infiltration was observed in control tumors. These 
findings demonstrate that Ab3 sera obtained from NUH82 or 91 immunized mice are 
very effective to eradicate established RCC, i.e., Ab2 vaccination may be able to 
eradicate (minimal) residual disease in RCC patients. 
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INTRODUCTION 
Anti-idiotype antibodies (Ab2) are defined as antibodies directed against the 
antigenic determinants (idiotope) located in the variable region of an immunoglobulin 
molecule. Ab2 which bear idiotopes mimicking the original antigen (so-called internal 
image antibodies) (1), may be able to substitute for a tumor-associated antigen (TAA) 
and may be used as tumor vaccines in patients with malignancies. Animal experiments 
have revealed that vaccination with internal image Ab2 can induce anti-anti-idiotype 
antibodies (Ab3) which mimic the initial antibody Abl (so-called Abl')(2), showing 
that Ab2 can substitute for a nominal antigen. Idiotype vaccination can also elicit 
antigen specific cellular responses (3-5). Several clinical trials with Ab2 have been 
reported for melanoma and colorectal cancer patients (6-7). This treatment resulted in 
significant prolongation of patient survival as compared to non-treated patients, 
indicating that vaccination with internal image Ab2 may represent a new therapeutic 
modality. 
We have previously isolated and characterized six internal image Ab2 
(NUH31, 51, 71, 82, 91; IgGl, NUH44; IgG2a) directed against a murine monoclonal 
antibody G250 (MAbG250) which specifically recognizes a RCC-associated antigen 
(G250), expressed on a large proportion of RCC (8). Fine specificity studies revealed 
that these Ab2 could be divided into four distinct groups, recognizing slightly different 
idiotopes in the Abl binding pocket; i) NUH31 and 51, ii) NUH44 and 82, iii) 
NUH71 and iv) NUH91 (9). We have also shown that vaccination with NUH31, 71, 
82 or 91, resulted in (partial) protection against RCC cell challenge (9). In related 
studies, we have demonstrated that MAbG250 and/or cytokine treatment in mice with 
established NU12 RCC xenografts resulted in significant tumor growth inhibition (10). 
Because Ab3 treatment immediately after tumor challenge is a rather artificial test 
system, very remote from Ab2 treatment of RCC patients with residual diseases, we 
have evaluated the anti-tumor efficacy of Ab3 sera obtained from mice immunized 
with NUH82 or NUH91 in mice with established s.c. transplanted RCC xenografts. 
These two Ab2 showed superior protection against tumor challenge. 
MATERIAL AND METHODS 
Animals 
Eight to ten-week-old female BALB/c mice were used for the preparation of 
Ab3 sera, and six-week-old female BALB/c nu/nu mice were used for tumor 
transplantation. All animals were purchased from the breeding facility of the 
University of Nijmegen, The Netherlands. Mice were maintained on a standard diet 
and water adlibitum. 
RCC xenograft 
The human RCC xenograft NU 12 (G250 antigen positive, G250+) was 
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established in our laboratory. The characteristics of NU 12 have been described 
elsewhere (11). This xenograft was passaged by serial s.c. transplantation. For 
transplantation, necrotic and hemorrhagic areas were carefully removed and viable 
tumor pieces of about 2-3 mm1 were implanted s.c. in the right flank of the mice. In 
this study, the 11th transplant generation was used. 
Monoclonal antibodies 
MAbG250 (IgGl), a murine monoclonal antibody which recognizes a RCC-
associated antigen expressed in the majority of RCC, was used to generate anti­
idiotype MAbs. Chimeric MAbG250 (IgGl) was kindly provided by Dr. S.O. 
Warnaar, Centocor (Leiden, The Netherlands). The characterization of MAbG250 has 
been described elsewhere (12). Murine internal image anti-idiotype monoclonal 
antibodies, NUH82 and 91 which define different, overlapping antigenic determinants 
in the paratope of MAbG250 have been described elsewhere (8). Immunoglobulins 
were purified from mouse ascites fluid by protein A chromatography. Monoclonal 
antibody against mouse macrophage MAC-I (Serotek Uden, the Netherlands) was used 
for immunohistological analysis. Mouse myeloma protein MOPC-21 (Sigma, St Louis, 
MO) was used as an isotype-matched control. 
Ab3 antisera preparation 
BALB/c mice were immunized i.p. with .50 μg of NUH82, 91 or MOPC21 
conjugated to Keyhole Limpets Hemocyanin (KLH, Sigma, St Louis, MO) emulsified 
with complete Freund's adjuvant and subsequently boosted with the same amount of 
immunogens emulsified with incomplete Freund's adjuvant (IFA) every three weeks. 
Seven days after the third booster, sera were harvested and used. 
Experimental design 
NU/nu BALB/c mice carrying NU 12 RCC xenografts of approximately 20-30 
mm
3
 (2-3 weeks after transplantation), were randomised and treatment was started. 
Each experimental group contained 6 mice. Group A was treated with serum obtained 
from the mice immunized with MOPC21-KLH (АЬЗ-MOPC), Group В received 
MAbG250, Group С received serum from NUH82-KLH immunized mice (Ab3-82), 
and Group D received serum from NUH91-KLH immunized mice (Ab3-91). Mice 
received i.p. injections of 200 μΐ АЬЗ serum or 250 μg MAbG250, 3 times a week 
during 6 weeks. Each tumor was measured twice a week with sliding digital calliper 
(Mitsutoyo, U.K.). Tumor volume was expressed as the Tumor Size Index (T.S.I.) 
and calculated by the following formula: 
T.S.I.(mm3) = L χ W χ Η /2 
where L, W and Η represent maximum diameter, diameter at right angles to the 
length, and thickness, respectively. 1-2 weeks after cessation of the treatment, mice 
were sacrificed and tumors were weighed. 
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Serological analysis 
To investigate whether Ab3 sera contained Abl\ antigen binding ELISA and 
competitive RIA with 125I-cG250 as a competitor were carried out as described 
previously (9). Briefly, 96-well flat-bottom microtiter plates coated with G250+ cell 
lysates were blocked with 1 % BSA/PBS and incubated with serial dilutions of Ab3 
sera for 1 hr at room temperature. After 3 washes, goat anti-mouse IgG conjugated 
to horse radish peroxidase (Dako, Denmark) was added and incubated for 1 hr at 
room temperature. After 3 washes, the wells were developed with 3,3\5,5'-
tetramethylbenzidin/0.03 % H 2 0 2 for 15 minutes. The reaction was stopped with 2.5 
M H2S04 and optical density was read at 450 nm. In the competitive assay, microtiter 
plates coated with G250+ cell lysates and blocked with BSA/PBS were incubated with 
100 μΐ of serial dilutions of the sera for Ihr at room temperature. A fixed amount of 
l25I-cG250 was added and incubated for 1 hr at room temperature. After 4 washes with 
BSA/PBS, bound radioactivity was determined. 
The presence of circulating antibodies in sera harvested seven days after 
cessation of treatment from mice treated with MAbG250 or Ab3 sera was determined 
by antigen binding ELISA as described above. 
Immunohistological analysis 
Tumor were snap-frozen seven days after cessation of treatment and stored in 
liquid nitrogen. The tumors were examined morphologically with hematoxylin-eosin 
staining, as well as immunohistologically for the presence of bound MAbG250 or 
Ab3, and for the presence of infiltrating mouse macrophages. Immunohistchemistry 
was performed as follows: 4-5 micron thick cryostat sections were dried for 1 hr and 
fixed in acetone for 10 min. at room temperature. After washing in phosphate buffered 
saline (PBS), tissue sections were incubated for 1 hr at room temperature with the 
corresponding Ab2 conjugated to horseradish peroxidase (HRPO) or M Ab M AC-I. 
After 3 washes with PBS, MAC-1 incubated sections were incubated with rabbit-anti-
rat Ig conjugated to horse radish peroxidase (Dako), preincubated with 20 % normal 
mouse serum. Tumor sections were developed with 3-3,diamiobenzidine and 0.01 % 
H 20 2 for 10 min at room temperature. After washing with tap water, the slides were 
counterstained with hematoxylin, and mounted with permount. 
Statistical analysis 
Groups of 5-6 mice were used and the experiment was performed twice. The 
difference between groups was analyzed using the Student-t test; ρ < 0.05 was 
considered significant. 
106 Chapter VI 
RESULTS 
Detection of anti-anti-idiotype antibodies 
In agreement with our earlier studies, Ab3 sera from NUH82 or NUH91 
immunized mice showed a dose dependent reaction with G250 antigen positive 
(G250+) cell lysates. No reaction was observed with G250 antigen negative (G250) 
cell lysates. Sera from mice immunized with MOPC21 did not show binding to G250+ 
or G250" cell lysates. To investigate how much Ab Γ was present in Ab3 sera, we 
compared the antigen binding capacity of MAbG250 and Ab3 sera (Fig. 1A and B). 
Based on this comparison, the Ab Γ concentration of Ab3-82 and Ab3-91 were 
estimated at 156 μg/ml and 143 /¿g/ml respectively, i.e., mice treated with 0.2 ml Ab3 
serum/dose received approximately 31.2 μg and 28.6 μg, АЬГ-82 and АЬГ-91 
respectively. 
Anti-tumor effects of Ab3 sera and MAbG250 
To investigate whether Ab2 vaccination could cure mice with established RCC 
xenografts (T.S.L approximately 20-30 mm3), mice were treated with Ab3 sera 
obtained from the mice immunized with NUH82, 91, MOPC21, or treated with 
MAbG250. Ab3-82 and Ab3-91 treated mice received approximately 30 /ig Abi '/dose, 
whereas MAbG250 treated mice received 250 μg/dose. The tumor volume 6 weeks 
after initiation of Ab3-82 or Ab3-91 treatment were significantly lower as compared 
to control animals (Ab3-MOPC21) (p<0.01, Fig. 2 and table I). Percent inhibition 
of tumor growth after 6 weeks of treatment was approximately 91 % (Ab3-82) and 84 
% (Ab3-91), respectively, as compared to control tumors. Treatment of mice with 250 
μg MAbG250/dose for six weeks also resulted in significant tumor growth inhibition 
(65 %) in agreement with earlier studies (p<0.05, Fig. 2 and table I)(9). Although 
the tumor growth inhibition of АЬЗ-NUH treated mice was greater than MAbG250 
treated animals, this difference was not significant (p>0.1). All mice treated with 
Ab3-MOPC showed tumor growth with unaltered tumor doubling time (11), indicating 
that treatment with АЬЗ-MOPC did not influence tumor growth. 
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Fig. 1. Antigen binding ELISA with АЬЗ-sera (A) and MAbG250 (B). Microtiter plates coated with 
G250+ cell lysates were incubated with serial dilutions of АЬЗ-82, АЬЗ-91, АЬЗ-МОРС (A), or serial 
concentrations of MAbG250 (B) for 1 hr. After washing, bound Ig was detected with goat anti-mouse 
IgG Fc conjugated to HRPO. 
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week 
Fig. 2. Anti-tumor effects of АЬЗ therapy, in mice with established RCC xenografts. Significant 
reduction in tumor growth was achieved with Ab3-82, -91, or MAbG250 treatment as compared to 
Ab3-MOPC treated mice (*; ρ< 0.01, **; ρ < 0.05 v.s. АЬЗ-МОРС treated tumors). 
Table I. Summary of tumor volume 
Group 
A 
В 
С 
D 
Treatment 
АЬЗ-МОРС 
MAbG250 
АЬЗ-82 
АЬЗ-91 
No. of 
mice 
6 
6 
6 
6 
Tumor 
Min 
168.8 
67.5 
0 
19.0 
size index (6w) 
Max Mean(TSI±SE) 
537.3 
153.0 
60.9 
68.4 
303.8±66.0 
107.8116.9** 
25.6±12.5* 
49.3 ±9.4* 
% inhibition 
65 
91 
84 
significant differences; * p<0.01, ** p<0.05 
Table. 1. Tumor volumes of nu/nu mice bearing NU 12 human RCC xenografts in the right flank 
treated with i.p. injections of АЬЗ-МОРС, MAbG250, Ab3-82, or Ab3-91 3 times a week for 6 
weeks. Tumors were measured twice a week and the volumes are expressed as mean T. S. I. ± SE. 
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Fig. 3 shows individual tumor growth curves of mice in each treatment group. 
Of Ab3-82 treated mice, two showed complete tumor regression starting immediately 
after initiation of therapy. Two tumors showed slow growth for 2-3 weeks whereafter 
tumors started to regress. In the remaining two mice, tumor regression was not 
observed. However, these tumors were significantly smaller than control tumors (less 
than 70 mm3 at week 7, Fig. 3C, as compared to 300 mm3 in controls, Fig. ЗА). Of 
mice treated with Ab3-91, one showed tumor regression 4 weeks after the treatment 
started and achieved complete tumor regression 3 weeks later. Two tumors stabilized 
at their start volume (20-30 mm3) and the other three tumors continued to grow 
slowly. One of these three tumors stabilized after week 5, resulting in a 48 mm3 tumor 
at week 7. The other tumors measured less than 80 mm3 at week 7 (Fig. 3D). The 
treatment with control sera resulted in unaltered tumor growth (Fig. ЗА). In the 
MAbG250 treatment group, two mice showed tumor stabilization after week 5, 
whereas the other tumors continued to grow, albeit much slower than tumors in the 
control group (compare Fig. ЗА and B). Immediately after cessation of MAbG250 
therapy, these four slowly growing tumors regained normal tumor doubling time. The 
tumor growth inhibition with NUH-АЬЗ sera treatment was considerably higher as 
compared to MAbG250 treatment (Fig 3, compare B,C,D). In mice without 
macroscopic evidence of tumor, no microscopic evidence of tumor was found. 
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Fig. 3. Tumor growth m individual mice treated with АЬЗ-MOPC (A), MAbG250 (В), Ab3-82 (C), 
and Ab3-91 (D) Tumor bearing mice were treated with ι ρ injections of Ab3 sera or MAbG250 for 
6 weeks Tumor volumes are expressed as mean Τ S I ± SE Arrow indicates cessation of 
treatment 
To investigate whether circulating Ab Γ or MAbG250 persisted at detectable 
levels, antigen binding ELISA as well as competitive RIA with 125I-cG250 were 
carried out seven days after cessation of treatment. Abl ' was not detected in sera from 
the АЬЗ-NUH treated mice (Fig. 4). In contrast, high levels of MAbG250, 
approximately 30 /ug/ml, were detected in sera from the MAbG250 treated mice 
(compare Fig. 1A and 4). 
2.00 г 
0.00 
1:10 1.50 1:100 1-200 1.400 
antisera dilution 
Fig. 4. Detection of circulating anti-anti-idiotype antibody (АЬГ) in sera from the mice treated with 
MAbG250, Ab3-82, Ab3-91 or АЬЗ-MOPC Microtiter plates were coated with G250-positive cell 
lysates and incubated with serial dilutions of the sera After washes with BS A/PBS, bound Ab3 was 
detected with goat anti-mouse IgG conjugated to HRPO 
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Histological analysis of NU 12 RCC xenografts 
In view of our earlier study where we noted that Abl treated tumors 
immediately regain the original doubling time after cessation of therapy, all mice were 
sacrificed 1-2 weeks after cessation of the treatment, to be able to investigate the 
effects of the different therapies. The morphology of the NU 12 tumors treated with 
Ab3-MOPC21 was identical to untreated NU 12 tumors. The tumors consisted of large 
clear cells without any visible infiltrating mouse cells. The tumors were encapsulated 
by mouse stromal cells with few infiltrating cells (Fig. 5A). In MAbG250 treated 
tumors, infiltrating mouse cells were observed in the viable tumor cells which was 
encapsulate by mouse stroma (Fig. 5B). In АЬЗ-NUH treated tumors, massive 
infiltrates of mouse cells surrounding necrotic areas were observed (Fig 5C). 
Phenotyping indicated that these infiltrates consist of macrophages. No Ab Γ could be 
detected on the tumors by immunohistochemistry (data not shown). 
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Fig, 5. Histopathologic findings of NU 12 tumors treated with АЬЗ-MOPC (A), MAbG250 (B), and 
Ab3-82 (C). Hematoxylin/eosin stain, original magnification 40x. 
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DISCUSSION 
In our previous study, we studied the anti-tumor effects of Ab2 vaccination 
in protection experiments (10). In the present study, the anti-tumor effects of NUH82 
and NUH91, which showed the best protection, were investigated in an established 
RCC tumor model. Treatment of mice bearing established NU 12 human RCC 
xenografts with Ab3-82 or Ab3-91 resulted in profound tumor growth inhibition 
(p<0.01) as compared to control tumors treated with sera from MOPC21 immunized 
mice. The percent tumor growth inhibition as compared to control tumors after 6 
weeks of treatment were 91 % for Ab3-82, and 84 % for Ab3-91, respectively. In a 
number of cases, complete tumor regression was seen, whereas tumors stabilized in 
the remaining animals. Furthermore, we treated NU 12 tumor bearing mice with 
MAbG250 (Abl). This also resulted in significant tumor growth inhibition (65 %, 
ρ<0.05) as compared to control tumor, in agreement with earlier studies (10). 
Although the amount of Ab Γ was 8-fold lower (approximately 30 μg) than 
Abl (250 μg), treatment with АЬЗ-NUH seemed more effective than MAbG250 
treatment Fig. 3 and Table I). In addition, serological analysis of sera from Abl 
treated mice revealed that even 7 days after cessation of Abl treatment, serum Abl 
levels were still very substantial (approximately 30 Mg/ml serum), whereas no АЬГ 
could be detected in АЬЗ-NUH treated mice, indicating that very high levels of Abl 
are necessary for tumor control in comparison to АЬГ level. It is likely that the 
polyclonal АЬГ population is more effective in recruitment of effector cells than the 
monoclonal Abl that is presenting only one Fc receptor to effector cells. Alternatively, 
the results can be explained by the fact that we injected whole serum including АЬГ, 
a number of circulating serum factors, e.g., cytokines such as IFNs and TNF and Τ 
cell factors (TCF) such as antigen specific macrophage arming factor (SMAF) and 
Mast cell arming Τ cell factor (MTCF) (13). We have previously shown that Ab2 
immunization elicits antigen specific cellular immune responses in mice, including the 
presence of antigen specific Τ cell factors (14). Therefore, it is feasible that the 
improved efficacy of Ab3 sera is due to the presence of these factors. However, we 
also have shown that very high dose of IFNs and TNF-α were necessary for NU 12 
tumor control (IFN-a or -τ: 150U/g body weight, TNF-a: 30,000U/g body 
weight)(9). It is unlikely that similar levels of these cytokines were achieved by Ab2 
immunization, and therefore it is implausible that cytokines in Ab3 sera played a role 
in the tumor regression observed in АЬЗ-NUH treated animals. 
Histological analysis demonstrated the presence of massive infiltrates in АЬЗ-
NUH treated tumors, whereas little or no infiltration in MAbG250 treated tumors or 
Ab3-MOPC21 treated tumors were found. Phenotyping showed that the infiltrates 
consisted of macrophages. In our previous study where animals were treated with IFN 
and/or TNF and/or Abl, mouse macrophage infiltration was observed only in tumors 
treated with MAbG250 in combination with IFN-a/TNF-α. Treatment of NU 12 
tumors with IFN-a/TNF-a, IFN-T/TNF-Q:, or MAbG250 alone did not result in any 
morphological alterations (9). We reasoned that administration of these cytokines 
might have resulted in activation of monocytes/macrophages, resulting in increased 
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ADCC by MAbG250 With Ab3 sera no addition of cytokines was necessary to 
achieve massive macrophage infiltration As mentioned earlier, Ab Γ may be very 
effective in recruiting effector cells such as NK cells and macrophages, since Ab Γ is 
a polyclonal population with the possibility to engage different effector mechanisms 
Alternatively, antigen-specific Τ cell factors may have targeted these cells to the tumor 
cells 
Induction of anti-tumor responses by vaccination with anti-idiotype antibodies, 
with and without Ab3 induction, have been shown by several investigators (15-17) 
Recently, it has been demonstrated that ldiotype vaccination may be effective in the 
treatment of infectious diseases ( 18-20) and malignancies (21 -26) Several anti-idiotype 
trials in cancer patients have shown the prolongation of survival of Ab2 vaccinated 
patients (7-8) Since survival rates for RCC patients with metastatic disease are very 
poor and current therapies are ineffective, Ab2 therapy may be a useful alterative for 
the treatment of RCC patients 
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SUMMARY AND CONCLUSIONS 
Although increasing success in the management of urological malignancies has 
been established, curative treatment of renal cell carcinoma (RCC) patients with 
metastatic disease still remains extremely difficult. In spite of a multitude of 
therapeutic agents, no improvement of the survival for these patients has been 
established in the last decade. It is well known that RCC is relatively resistant to 
conventional therapies, e.g., radio- and chemotherapy, and immunotherapy seems to 
be the most promising treatment for disseminated RCC (1). However, although 
treatment with biological response modifiers (BRMs) has shown some efficacy in 
selected metastatic RCC patients, response rates hardly exceed 30 % (2). Clearly, the 
development of new therapeutic modalities is necessary. 
In this thesis, the possible therapeutic application of monoclonal antibody 
G250 (MabG250) and internal image anti-idiotype antibodies resembling the G250 
antigen for human RCC were investigated. 
In chapter I, a general description of the clinical aspects of human RCC and 
an overview of the therapeutic modalities for RCC patients including cytokines, 
adoptive cellular treatments and monoclonal antibodies (Mab) are given. In addition, 
an overview of the idiotype network concept and its therapeutic applications for 
infectious diseases and malignancies as idiotype vaccines is discussed. 
In chapter II, the anti-tumor effects of MabG250 (Abl) in combination with 
cytokines (interferon-α; IFN-a, interferon-r; IFN-r, tumor necrosis factor-α; TNF-a) 
on established human RCC NU 12 tumors growing in immuno-deficient mice (so-called 
xenografts) are described. Treatment of tumor bearing mice with MAbG250, or IFN-
a/TNF-a, or IFN-r/TNF-a, resulted in significant tumor growth inhibition. Treatment 
with MAbG250 in combination with IFN-a/TNF-a resulted in an enhanced reduction 
of tumor growth. In some cases, mice were cured. However, tumor responding to the 
combination therapy, but not in complete remission, started to grow immediately after 
cessation of the therapy. Immunohistochemical analysis revealed massive infiltration 
of macrophages in tumors treated with MAbG250/IFN-a/TNF-a, suggesting that 
complement mediated lysis and antibody-dependent cellular cytoxicity mediated by 
natural killer cells and/or macrophages played a role in tumor regression. 
In chapter III, the generation and characterization of six anti-idiotype 
monoclonal antibodies (Ab2)(NUH31, 51, 71, 82, 91: IgGl, NUH44: IgG2a) are 
presented. Inhibitory and competitive radioimmunoassays (RIA) revealed that all Ab2 
were MabG250 (Abl) binding site specific, indicating that they bear the internal image 
of RCC-associated antigen G250. Cross-blocking RIA revealed that these Ab2 
recognized partly overlapping epitopes on Abl. Since internal image Ab2 must be able 
to substitute for the nominal antigen, we investigated whether these Ab2 could induce 
anti-anti-idiotype antibodies (Ab3) resembling Abl (АЬГ). Immunization of rabbits 
with these Ab2 indeed resulted in the induction of antigen specific АЬГ, showing that 
all Ab2 could substitude for the nominal antigen. 
Although Ab2 can induce antigen specific humoral responses as described in 
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chapter III, tumor specific cell-mediated immunity may play an important role in 
tumor therapy. Τ cell responses induced by Ab2 have been investigated in 
experimental and clinical studies (3-6). In chapter IV, the investigations concerning 
the induction of antigen specific cell mediated immunity are described. Ab2 
immunized mice were challenged with antigen-positive (G250+) and/or -negative 
(G250) cells in the ear pinna and delayed type hypersensitivity reactions (DTH) were 
measured. For all six Ab2, challenge with G250+ cells resulted in a profound DTH 
reaction whereas no DTH reaction was observed with G250' cells. The G250-specific 
DTH reaction demonstrated a biphasic pattern with an early (2 hr) and late (classical) 
reaction (24 and 48 hr). Both early and late reactions were anti-idiotype M Ab specific 
as immunization with irrelevant IgG did not result in any DTH response. To confirm 
the cellular nature of the DTH responses, lymphocytes or serum harvested from mice 
sensitized with Ab2 were transferred to naive mice which were subsequently 
challenged with G250+ and G250" cells. Tumor challenge of cellular transferred mice 
resulted in similar DTH responses as compared to sensitized mice, whereas serum 
transfer only showed a reaction 2 hours after tumor challenge, confirming that the 
DTH reactions were cell mediated. The 2 hour response of the serum transferred mice 
could be explained by the presence of tumor-specific Τ cell factors. 
In chapter V, we further studied the fine specificity of these Ab2 and 
investigated whether the immunogenicity of Ab2 could be enhanced by conjugation to 
a carrier. Fine specificity studies of mice and rabbit Ab3 sera revealed that the six 
Ab2s could be divided into four mutually exclusive groups. NUH71 and NUH91 
induced Ab3 sera could compete with Abl when the corresponding Ab2 was present, 
suggesting that they bear unique epitopes. The remaining Ab3 sera could be divided 
into two groups:NUH31- and 51-Ab3 sera, and NUH44- and 82-Ab3 sera. NUH31-
Ab3 sera bound equally well to NUH51 and NUH44-Ab3 sera to NUH82, and vice 
versa. Taken together, these results indicate that subtle differences between the six 
Ab2 exist. Nevertheless, all Ab2 induce RCC-specific Abl\ Immunization with Ab2 
conjugated to a carrier protein resulted in an approximately two-fold increase in 
antigen-specific Ab3 as compared to immunization with Ab2 alone. 
To investigate the anti-tumor effects of Ab2 treatment, immuun-deficient mice 
carrying small established human RCC NU 12 xenografts (G250+, 20 mm3) or 
receiving a subcutanous injection of 2 χ IO5 SK-RC-52 (G250+) RCC cells were 
treated by intraperitoneal injection of 0.2 ml Ab3 sera (chapter V-VI). Treatment of 
SK-RC-52 injected mice with any of the Ab3 sera from Ab2 immunized mice resulted 
in significant tumor growth inhibition (p<0.01) and lower tumor take as compared 
to control groups. These results indicate that the mice were protected against tumor 
cell challenge. In mice with established RCC xenografts, significant reduction in tumor 
growth was achieved. In some АЬЗ-NUH treated mice, complete tumor regression was 
observed 5-7 weeks after initiation of treatment. In contrast, treatment with control 
sera resulted in 100 % tumor-take and no effect on the tumor doubling time. The 
therapeutic efficacy of Ab3 sera was higher than MAbG250 treatment. Histological 
examination revealed massive infiltration of NUH-АЬЗ treated tumors, whereas no 
infiltrating cells were observed in control tumors. These findings suggest that Ab2 
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vaccination can elicit powerful anti-tumor effects in immune competent animals. 
The studies in this thesis deal with the possible therapeutic application of monoclonal 
antibody G250 and anti-idiotype antibodies as tumor vaccines for RCC patients. 
Because of the lack of effective treatment, the use anti-tumor MAbs or anti-idiotype 
MAbs in active specific immunotherapy seems promising. However, the use of anti­
idiotype antibodies as tumor vaccines in clinical trials has been limited (6-7). The 
results described in this thesis show that RCC tumor-antigen-associated related 
idiotype vaccination induces antigen-specific humoral as well as cellular responses, 
resulting in tumor regression in an animal model. A clinical trial is necessary to 
investigate whether immunization of RCC patients with Ab2 will result in similar 
specific anti-RCC responses. 
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SAMENVATTING EN CONCLUSIES 
Hoewel in toenemende mate succes wordt bereikt bij de behandeling van 
urologische maligniteiten, blijft een behandeling van niercelcarcinoom (NCC) patiënten 
met uitzaaiingen leidend tot volledige genezing nog steeds bijzonder moeilijk. Ondanks 
een veelheid aan therapeutische middelen is geen verbetering in de overleving van 
deze patiënten bewerkstelligd in de laatste decade. Het is bekend dat NCC relatief 
resistent is tegen conventionele therapieën zoals radio- en chemotherapie, en 
immunothérapie lijkt de meest veelbelovende behandeling voor uitgezaaid NCC (1). 
Echter, hoewel behandeling met cytokines enig effect heeft vertoond in geselecteerde 
NCC patiënten, overschrijdt de anti-tumor reactie nauwelijks 30% (2). Het is 
overduidelijk dat de ontwikkeling van nieuwe therapeutische middelen noodzakelijk 
is. 
In dit proefschrift worden de mogelijke therapeutische toepassingen van het 
monospecifieke antilichaam G250 (MalG250) en van spiegelbeeld anti-idiotype 
antilichamen gelijkend op het G250 antigeen voor humaan NCC onderzocht. 
In hoofdstuk I wordt een algemene beschrijving van de klinische aspecten van 
het humane NCC gegeven alsmede een overzicht van de therapeutische modaliteiten 
voor NCC patiënten, inclusief cytokines, adoptieve cellulaire therapie en 
monospecifieke antilichamen (Mal). Tevens wordt een overzicht gegeven van het anti-
idiotype netwerk concept en de therapeutische toepassingen als idiotype vaccin in 
infectieziekten en tumoren. 
In hoofdstuk II wordt het anti-tumor effect van MalG250 (All) in combinatie 
met cytokines (interferon-α; IFN-α, interferon-τ; IFN-τ, tumor necrose factor-α; 
TNF-α) op gevestigde humane NCC NU 12 tumoren groeiend op immuun-deficiënte 
muizen (zgn. xenograften) beschreven. Behandeling van tumor dragende muizen met 
MalG250, of IFN-a/TNF-a, of IFN-r/TNF-a, resulteerde in een significante tumor 
groei remming. Behandeling met MalG250 in combinatie met IFN-7/TNF-a 
resulteerde in een verhoogde reductie van tumor groei. In sommige gevallen waren de 
muizen genezen. Echter, tumoren die reageerden op de combinatie therapie maar nog 
niet geheel in remissie waren begonnen direct na het beëindigen van de behandeling 
weer te groeien. Immunohistochemische analyse onthulde massieve infiltratie van 
macrofagen in tumoren behandeld met MabG250/IFN-T/TNF-a, suggererend dat 
complement gemedieerde lysis en antilichaam afhankelijke cellulaire cytotoxic 
gemedieerd door "natural killer" (NK) cellen en/of macrofagen een rol speelden in 
tumor regressie. 
In hoofdstuk III wordt de ontwikkeling en karakterisering van zes anti-idiotype 
monospecifieke antilichamen (A12)(NUH31, 51, 71, 82, 91: IgGl, NUH44: IgG2a) 
gepresenteerd. Inhibitie en competitieve radioimmunoassays (RIA) toonden aan dat alle 
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A12 specifiek waren voor de bindingsplaats van MalG250 (All), aantonend dat ze het 
spiegelbeeld dragen van het NCC-geassocieerde antigeen G250. Kruis-blokkerende 
RIA toonden aan dat deze A12 gedeeltelijk overlappende epitopen op All herkennen. 
Aangezien spiegelbeeld A12 moeten kunnen substitueren voor het nominale antigeen, 
is onderzocht of deze A12 anti-anti-idiotype antilichamen (A13) konden induceren die 
op All leken (Α1Γ). Immunizatie van konijnen met deze A12 resulteerde inderdaad in 
de inductie van antigeen specifieke Α1Γ, aantonend dat alle A12 kunnen substitueren 
voor het nominale antigeen. 
Hoewel A12 antigeen specifieke humorale reacties kunnen induceren zoals 
beschreven in hoofdstuk III, kan tumor specifieke cellulair gemedieerde immuniteit een 
belangrijke rol spelen in tumor therapie. Τ cel reacties geïnduceerd door A12 zijn 
onderzocht in experimentele en klinische studies (3-6). In hoofdstuk IV wordt 
onderzoek betrekking hebbend op de inductie van antigeen specifieke cellulair 
gemedieerde immuniteit beschreven. Muizen geïmmuniseerd met A12 werden 
geïnjecteerd met antigeen-positieve (G250+) en/of-negatieve (G250) cellen in de oor 
pinnae en vertraagd type hypersensitiviteits reacties (VTH) werden gemeten. Voor alle 
zes A12 resulteerde injectie met G250+ cellen in een opmerkelijke VTH reactie terwijl 
geen VTH opgemerkt werd met G250_ cellen. De G250-specifieke VTH reactie 
vertoonde een bi-fasisch patroon met een vroege (2 uur) en late (klassieke) reactie (24 
en 48 uur). Zowel de vroege als de late reacties waren anti-idiotype MAI specifiek 
aangezien immunizatie met irrelevant IgG niet resulteerde in enige VTH reactie. Ter 
bevestiging van het cellulaire karakter van de VTH reacties werden lymfocyten of 
serum verkregen uit muizen die gesensitiseerd waren met A12 overgebracht naar 
onbehandelde muizen die vervolgens geïnjecteerd werden met G250+ en G250 cellen. 
Tumor injectie van muizen die lymphocyten ontvangen hadden resulteerde in een VTH 
reactie die vergelijkbaar was met de geïmmuniseerde muizen, terwijl het overbrengen 
van serum slechts een reactie teweeg bracht 2 uur na tumor injectie, bevestigend dat 
de VTH reacties door cellen teweeg gebracht werd. De 2 uur reactie van de muizen 
die serum ontvingen kon verklaard worden door de aanwezigheid van tumor-specifieke 
Τ cel factoren. 
In hoofdstuk V hebben we de fijnspecificiteit van deze A12 verder bestudeerd 
en onderzocht of de immunogeniciteit van A12 verhoogd kon worden door de 
conjugatie aan een drager. Fijnspecificiteitsstudies van muis en konijn Ab3 sera 
toonden aan dat de zes Ab2 verdeeld konden worden in vier afzonderlijke, unieke 
groepen. NUH71 en NUH91 geïnduceerde Ab3 sera konden slechts competeren met 
All wanneer het corresponderende Ab2 aanwezig was, suggererend dat ze unieke 
epitopen dragen. De overblijvende Ab3 sera konden in twee groepen verdeeld worden: 
NUH31- en 51-AI3 sera, en NUH44- en 82-Ab3 sera. NUH31-A13 sera bonden 
vergelijkbaar aan NUH51 en NUH44-A13 sera aan NUH82 en vice-versa. Tezamen 
genomen geven deze resultaten aan dat er subtiele verschillen tussen de zes A12 
bestaan. Desalniettemin induceren alle A12 NCC-specifieke Al Γ. Immunizatie met A12 
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geconjugeerd aan een dragereiwit resulteerde in ongeveer tweevoudige toename van 
antigeen-specifieke A13 vergeleken met immunizatie met A12 alleen. 
Ter studie van de anti-tumor effecten van A12 behandeling werden immuun-
deficiëntie muizen die kleine gevestigde NU 12 humane NCC xenografts droegen 
(G250+, 20mm3), of een subcutane injectie van 2 χ IO5 SK-RC-52 (G250+) NCC 
cellen kregen behandeld door intraperitoneale injectie met 0,2 ml A13 sera (hoofdstuk 
V-VI), Behandeling van SK-RC-52 geïnjecteerde muizen met elk van de A13 sera van 
A12 geïmmuniseerde muizen resulteerde in een significante tumor groei inhibitie 
(p<0,01) en lagere tumor opkomst vergeleken met controle groepen. Deze resultaten 
geven aan dat de muizen beschermd waren tegen tumor cel injectie. In muizen met 
gevestigde NCC tumoren werd significante tumor groei reductie bereikt. In sommige 
A13-NUH behandelde muizen werd volledige tumor regressie geobserveerd 5-7 weken 
na initiatie van de behandeling. Daarentegen resulteerde behandeling met controle sera 
in 100% tumor groei en geen effect op de tumor verdubbelingstijd. De therapeutische 
effectiviteit van de A13 sera was hoger dan MalG250 behandeling. Histologisch 
onderzoek toonde massieve infiltratie van NUH-A13 behandelde tumoren aan, terwijl 
geen infiltrerende cellen in de controle tumoren werden geobserveerd. Deze 
bevindingen suggereren dat Ab2 vaccinatie een krachtig anti-tumor effect in immuun 
competente dieren kan opwekken. 
De studies in dit proefschrift gaan over de mogelijke therapeutische applicatie 
van het monospecifieke antilichaam G250 en anti-idiotype antilichamen als tumor 
vaccin voor NCC patiënten. Omdat effectieve behandeling ontbreekt, lijkt het gebruik 
van anti-tumor Mal of anti-idiotype Mal in actieve specifieke immuuntherapie 
veelbelovend. Echter, het gebruik van anti-idiotype antilichamen als tumor vaccin in 
klinische onderzoekingen is gelimiteerd (6-7). De resultaten beschreven in dit 
proefschrift geven aan dat NCC tumor-geassocieerde antigeen gerelateerde idiotype 
vaccinatie antigeen-specifieke humorale zowel als cellulaire reacties induceert, 
resulterend in tumor regressie in een diermodel. Een klinische studie is noodzakelijk 
om te onderzoeken of immunizatie van NCC patiënten met A12 zal resulteren in 
vergelijkbare anti-NCC reacties. 
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